Molecular Mechanism and Prevention Strategy of Chemotherapy- and Radiotherapy-Induced Ovarian Damage.

1. Introduction

It is estimated that more than 9.2 million women were newly diagnosed with cancer worldwide in 2020 [ 1 ]. Furthermore, there were 89,500 new cancer cases and 9270 cancer deaths in adolescents and young adults (AYAs) aged 15–39 years in the United States [ 2 ]. The survival of cancer patients has significantly improved due to recent advances in cancer treatment [ 3 , 4 ]. However, oncologic therapies can affect ovarian function in young women [ 5 , 6 , 7 , 8 ]. The exhaustion of ovarian follicle reservoirs may lead to not only loss of fertility but also premature ovarian failure, which could result in poor quality of life in young female cancer survivors [ 9 , 10 , 11 ]. Recently, fertility preservation (FP) has become an emerging discipline with significant clinical value in the care of AYA cancer patients [ 12 , 13 , 14 ], and many organizations have provided recommendations for FP during cancer treatment [ 15 , 16 , 17 , 18 , 19 ].

Chemotherapy has toxic effects on the ovaries and causes the loss of the primordial follicle (PF) reserve [ 20 ]. Endocrine therapy can increase the risk of infertility in patients with hormone receptor-positive malignancies [ 21 ]. In the case of abdominal or pelvic cancers, treatments including radiotherapy or surgery may alter future fertility because of direct gonadal damage [ 22 , 23 ]. Many studies have explored the mechanisms implicated in ovarian toxicity during cancer treatment; however, the underlying molecular pathophysiology is not fully understood [ 24 , 25 , 26 , 27 , 28 ].

This article will review the mechanisms of cancer therapy-induced ovarian dysfunction and explore the future perspectives for preventing infertility in AYAs with cancer.

2. Regulation of the Ovarian Follicular Reserve

In the ovary, there is a finite number of PFs that continue to decline until menopause [ 29 ]. A single layer of granulosa cells (GCs) surrounds an immature oocyte to form each PF, which together constitute the “ovarian reserve”, which refers to the total population of PFs [ 30 ]. In mammals, the ovarian reserve is established early in life and then declines regularly throughout the reproductive years. In the human ovary, 85% of the potential oocytes are lost before birth [ 30 ]. PFs usually remain quiescent for years, and this quiescence is maintained by several molecules, including PTEN, the TSC1–TSC2 complex, Foxo3A, P27, anti-Müllerian hormone (AMH), and FoxL2 [ 31 ]. Most PFs then undergo atresia, but a minority of follicles reach the pre-ovulatory stage. The activation of dormant follicles is mediated by the upregulation of the PI3K/PTEN/Akt pathway [ 32 , 33 , 34 , 35 ]. The survival of PFs is regulated by PDK1 signaling or RPS6 [ 32 ]. Several studies have reported that the ovarian reserve is regulated by autophagy [ 36 , 37 ]. Bcl-2 and its associated proteins, such as BAX, play critical roles in the survival or apoptosis of PFs [ 32 ]. Therefore, a combination of follicular activation and multiple inhibitory/activator molecules is necessary to preserve the ovarian reserve, and any disturbance in these mechanisms may induce a premature loss of ovarian function [ 38 ].

3. Cancer Treatment-Induced Ovarian Damage

3.1. Mechanism of Chemotherapy-Induced Ovarian Damage

Chemotherapy can adversely affect the ovarian reserve [ 39 , 40 , 41 , 42 , 43 , 44 , 45 ]. Table 1 lists known gonadotoxic chemotherapy agents [ 29 , 45 , 46 , 47 ]. Chemotherapy-induced amenorrhea may be transient, and menstruation may recur after treatment completion. The oocytes and GCs are vulnerable to chemotherapeutic agents. Each agent may have a different mechanism of action on cancer cells, resulting in the cessation of the cell cycle.

3.1.1. PF Loss via DNA Alteration, Follicular Atresia, and Apoptosis

Chemotherapeutic agents can induce double-stranded breaks (DSBs) in DNA. If a DSB is repaired successfully, the cell survives via ataxia–telangiectasia mutated (ATM)-mediated DNA damage repair pathways. However, if the repair pathways fail, DNA damage can result in cellular apoptosis [ 48 ] ( Figure 1 ). Apoptosis in the ovary has been demonstrated in growing follicles and has been shown to originate in proliferating GCs [ 49 ]. Within mature oocytes, the P63 protein activates BAX and BAK proteins, which can be transmitted by the activation of Tap73, a P53-upregulated modulator of apoptosis, and phorbol-12-myristate-13-acetate-induced protein 1 [ 50 ]. Many studies have demonstrated these mechanisms in vitro and in vivo [ 51 , 52 , 53 , 54 , 55 ]. Notably, even chemotherapeutic agents with low gonadotoxicity can alter the development of growing follicles because mitotic cells are especially sensitive to chemotherapeutic agents [ 51 , 55 ].

3.1.2. Follicle Loss via Activation and “Burnout”

The PI3K/PTEN/Akt pathway terminates follicle dormancy, directly influences the oocytes and pre-GCs of PFs, and indirectly destroys large follicles [ 24 ]. The destruction of follicles induces the impairment of AMH and reduces the suppression of the PF pool, which is followed by the activation of PFs in an attempt to compensate for the decrease in the number of growing follicles [ 56 ]; this phenomenon is called the “burnout effect” [ 57 , 58 ] ( Figure 2 ). In a previous study, exposure to 3-methylcholanthrene, a carcinogen and ovotoxicant, resulted in PF activation and depletion [ 59 ], implying that the burnout effect triggers the growth of dormant follicles. However, this induction of dormant follicle growth is affected by the upregulation of the PI3K/PTEN/Akt pathway and substantial follicular apoptosis, which results in a reduction in AMH secretion. This could be caused by a direct effect on oocytes and pre-GCs [ 56 , 60 , 61 ]. Reduced AMH levels and enhanced follicular recruitment and atresia in patients with ovarian endometriosis may have the same effect [ 62 ]. However, the mechanism by which chemotherapeutic agents induce the activation of this pathway is still under investigation.

3.1.3. Stromal and Microvascular Damage

The ovarian stroma can be indirectly damaged by chemotherapeutic agents [ 29 , 63 ]. For example, the administration of doxorubicin results in a significant reduction in ovarian blood supply and small vessel spasms in the ovary [ 64 ]. Another study reported that chemotherapy led to stromal fibrosis and ovarian vascular abnormalities [ 65 ]. These findings imply that damage to blood vessels and focal fibrosis of the ovarian cortex could be another mechanism of chemotherapy-induced ovarian dysfunction [ 66 ]. Additionally, in patients previously exposed to chemotherapy, the ovaries show thickening and hyalinization of cortical stromal vessels caused by the disorganization of blood vessels in the ovarian cortex and cortical fibrosis [ 67 ]. The production of sex steroids decreases because of damage to endocrine ovarian function after exposure to chemotherapeutic agents [ 68 ]. This is also supported by a recent study that showed an inverse correlation between ovarian vascular density and PF apoptosis [ 69 ], thus suggesting an indirect mechanism by which chemotherapy-induced ovarian vascular injury reduces the number of PFs.

3.2. Radiation-Induced Ovarian Damage

Ionizing radiation to the abdominopelvic region has deleterious effects on gonadal function at all ages [ 70 ]. For example, cervical and rectal cancers usually require pelvic irradiation, and craniospinal radiotherapy is performed in cases of central nervous system malignancy. In some patients with Hodgkin’s disease, pelvic lymph nodes require irradiation, and total body irradiation may be necessary prior to bone marrow transplantation.

The resulting damage depends on the dose and field of irradiation and the age of the patient. Women who received radiation treatment outside the pelvis had a low risk of ovarian dysfunction [ 71 ]. In the prepubertal period, the ovaries are relatively resistant to gonadotoxicity [ 72 ].

3.2.1. Radiosensitivity of Oocytes

Dividing GCs appear to be the main target of radiation-related gonadotoxicity. Prominent cell death has been observed within a few hours of irradiation [ 73 ]. Oocytes are highly radiosensitive because the estimated dose at which half of the follicles are lost in humans (LD50) is <2 Gy [ 74 ]. A single oocyte is highly radiosensitive to a D 0 of 0.12 Gy (reciprocal of the slope of the exponential region of a survival curve). This sensitivity is affected by age; women younger than 40 years of age are less sensitive, requiring 20 Gy to experience permanent damage, whereas older women require only 6 Gy [ 75 ]. The radiosensitivity of oocytes differs according to their growth phase. A quiescent PF is usually more radio-resistant than a large maturing follicle [ 74 ]. Radiotherapy-induced ovarian damage also occurs in the stroma with vascular damage, resulting in tissue atrophy and fibrosis [ 73 ]. In general, a combination of multiple factors determines the extent of radiosensitivity, including age, the use of combination therapy, and radiation dose [ 76 ].

3.2.2. Linear Energy Transfer

The biological effect of radiation treatment is also affected by linear energy transfer (LET) in tumors [ 77 ]. LET radiation induces anticancer effects by depositing physical energy or radiation into malignant cells, which results in stable free radicals and induces cellular damage because of the direct ionization of the cellular macromolecules, such as DNA, RNA, lipids, and proteins [ 78 ]. High LET radiation results in gonadal DNA damage that causes multiple lesions within the helical turns of the DNA, which is referred to as “direct” damage ( Figure 3 ).

3.2.3. Oxidative Stress Resulting in DNA Damage

Radiotherapy also leads to the generation of reactive oxygen species (ROS) in cancer cells as a result of water radiolysis, inducing oxidative stress and the diminution of the antioxidant defense mechanisms, which could also affect healthy normal tissues, including the ovaries [ 79 ]. Thus, the imbalance between the free radicals and the oxidative radicals may play a role in the etiology of radiotherapy-induced gonadotoxicity [ 80 ]. Increased ROS levels induce rapid PF loss and female infertility via DNA damage, which is termed as “indirect” damage [ 81 ] ( Figure 3 ). ROS can induce apoptosis, leading to oxidative stress exerted on cellular macromolecules, ultimately activating the intrinsic mitochondrial pathway of apoptosis via p53 activation, which results in cytochrome c release and caspase activation [ 82 , 83 ]. Activated caspases cleave DNA damage repair enzymes to block cellular DNA repair and enhance apoptosis [ 84 ]. Another study identified increased activity of the MAPK signaling pathway in irradiation-induced GC apoptosis [ 85 ]. Human oocytes express DNA repair genes, but their role in the repair of radiation-induced genomic damage is unclear [ 86 ]. As ionizing radiation generates free radicals that induce DNA damage, compounds that scavenge free radicals may be useful for protection against radiation damage [ 87 ].

4. Detection of Ovarian Damage

4.1. Clinical Considerations

Older age is an important risk factor for ovarian damage compared to younger age. A significantly higher incidence of amenorrhea after chemotherapy was observed in female patients with breast cancer aged >40 years than in younger women [ 88 ]. Another study confirmed similar results [ 89 ]. A cross-sectional analysis of data from a prospective cohort study demonstrated that the ovarian reserve was impaired in a dose-dependent manner in patients exposed to cancer therapies, including chemotherapy or pelvic radiotherapy [ 90 ].

4.2. Biochemical Markers for Ovarian Reserve

4.2.1. AMH

AMH is produced by GCs from ovarian follicles, which are mainly small antral follicles. Typically, its level rapidly decreases with age and becomes undetectable during menopause [ 91 ]. Accordingly, AMH, at a low level, exhibits high sensitivity and specificity for chemotherapy-exposed women with poor ovarian reserve [ 92 ]. AMH levels before or after cancer treatment provide information regarding the diversity of gonadal damage according to the type of the chemotherapeutic agent and help predict long-term ovarian function [ 93 ]. Several studies have shown that there is an AMH level threshold that predicts the risk of amenorrhea after chemotherapy [ 94 , 95 , 96 ].

However, the level of AMH does not always correlate with the quality of oocytes because it only reflects the quantity of oocytes [ 97 ]. Additionally, AMH concentration could be altered by the handling of the blood sample or the assay method used to measure AMH levels [ 98 ].

4.2.2. Basal Follicle-Stimulating Hormone and Estradiol

Follicle-stimulating hormone (FSH) concentrations usually change throughout the menstrual cycle and can be best measured during the early follicular phase. Basal FSH, which is the FSH level during the early follicular phase, is widely used to determine ovarian reserve. FSH levels >10 IU/L on menstrual cycle day 2 or 3 may indicate a decreased ovarian reserve. Elevated FSH levels in young women with amenorrhea suggest premature ovarian insufficiency.

After chemotherapy, FSH levels usually increase due to follicular depletion. However, basal FSH is not always a valuable marker of ovarian reserve in patients who have undergone cancer treatment. For example, if women have regular menstrual cycles, FSH levels may show normal values, even though the ovarian reserve decreases after treatment [ 89 , 99 ]. In such instances, that is, when the FSH levels are within the normal range, estradiol concentration in the early follicular phase may provide additional information [ 100 ].

4.2.3. Inhibin-B

Inhibin-B is secreted by the GCs of antral follicles and it regulates FSH levels via a negative feedback reaction. Inhibin-B is usually exhibited at low levels in women with a decreased ovarian reserve [ 101 ]. However, it is not a reliable marker of the ovarian reserve because its levels vary widely during menstrual cycles [ 102 ].

4.3. Ultrasonographic Markers

During the early follicular phase, transvaginal ultrasound can be used to count antral follicles measuring 2–10 mm in both ovaries [ 103 ]. A low AFC may be related to a diminished response to ovarian stimulation. Furthermore, a few studies have demonstrated that a low AFC could be a marker for the risk of developing amenorrhea after cancer treatment [ 94 , 96 ]. However, the estimation of ovarian volume using ultrasound provides limited clinical utility as an ovarian reserve marker.

5. Prevention and Management of Ovarian Damage

FP options could be differentiated by patient age, desire for conception, treatment regimen, socioeconomic status, and treatment duration ( Figure 4 ) [ 45 ]. Such options include the use of hormonal medications for ovarian suppression, various methods for protecting the ovaries during radiotherapy, cryopreservation, in vitro oocyte maturation, artificial ovaries, and stem cell technologies.

5.1. Prevention of Chemotherapy-Induced Ovarian Damage

With conventional chemotherapy regimens, cytotoxicity-associated ovarian insufficiency involves PF pool depletion by apoptosis or hyperactivation mechanisms, notably mediated by the ABL/TAp63 and PI3K/Akt/mTOR pathways ( Figure 5 ).

5.1.1. Gonadotropin-Releasing Hormone (GnRH) Agonists

GnRH agonists are hormonal medications that modulate gonadotropins and sex hormones [ 104 ]. Ovarian suppression via the administration of a GnRH agonist before or during chemotherapy may have protective effects on the ovaries by downregulating the secretion of FSH and pituitary luteinizing hormone [ 105 ]. Previous studies have shown that ovarian suppression with GnRH agonists during chemotherapy protects ovarian function in AYAs treated for lymphoma, breast cancer, and other diseases [ 106 , 107 , 108 ]. The American Society of Clinical Oncology guidelines state that there are conflicting recommendations regarding GnRH agonists and other means of ovarian suppression for FP [ 15 ].

GnRH analogs have two possible mechanisms of action [ 109 , 110 , 111 ]. The first involves decreasing the sensitivity of the PFs entering the growing pool to gonadotoxicity by the administration of a GnRH agonist. The second constitutes the direct anti-apoptotic effect of GnRH agonists on ovarian germline stem cells. Several studies have demonstrated that the use of GnRH agonists reduces chemotherapy-induced ovarian damage; however, the mechanism underlying the protective effect on ovaries remains unclear [ 112 , 113 , 114 , 115 , 116 , 117 ]. Therefore, the use of GnRH agonists is considered suitable for AYAs with cancers for whom other established FP options are not suitable—such as cryopreservation—to reduce chemotherapy-induced ovarian insufficiency. The use of GnRH agonists, in combination with other modalities, including oocyte or embryo freezing, may be a good option [ 118 ]. GnRH agonists usually do not have a protective effect against radiation treatment-induced gonadotoxicity [ 119 , 120 ].

5.1.2. AS101

AS101 is a non-toxic immunomodulator that acts on the PI3K/PTEN/Akt pathway [ 121 ]. AS101 is known to inhibit Akt activation in mouse multiple myeloma cell lines [ 122 ]. An in vivo study demonstrated that AS101 was effective in reducing apoptosis in the GCs of growing follicles by regulating the PI3K/PTEN/Akt pathway [ 123 ]. Moreover, AS101 does not interfere with the therapeutic effect of chemotherapy and in fact shows synergistic antitumor activity [ 124 , 125 , 126 , 127 ]. According to an in vivo study using cyclophosphamide-treated mice, cyclophosphamide induced an increase in early growing follicles and an increased ratio of growing/dormant follicles was observed histologically. This suggests that cyclophosphamide-induced primordial follicle loss is not due to apoptosis, but the activation of primordial follicles to undergo recruitment and growth. AS101 cotreatment reduces cyclophosphamide-induced activation of PTEN/PI3K/Akt pathway proteins in the ovaries. AS101 was also found to reduce follicle loss and improve AMH concentration after cyclophosphamide treatment. In addition to preventing follicle loss and maintaining fertility, AS101 also has the added benefit of improving the responsiveness of breast cancer cells to cyclophosphamide chemotherapy [ 122 ].

5.1.3. Anti-Müllerian Hormone (AMH)

AMH is produced in GCs of growing follicles and has a suppressive effect on follicle activation [ 128 , 129 , 130 ]. AMH inhibits PF recruitment and growth, and the loss of AMH results in the depletion of the PF pool. A previous study confirmed that the initiation of primordial follicle growth was inhibited when human ovarian cortical tissue was cultured with recombinant AMH [ 127 ]. The combination of recombinant AMH with the cyclophosphamide metabolite in an ex vivo culture system maintained a high number of PFs in the ovaries [ 24 ]. Moreover, when recombinant AMH was administered together in a model of CY-treated pubertal mice, FOXO3A phosphorylation, the main factor for PMF activation, was significantly reduced. The pPS6K level was decreased in the mice treated with AMH compared to the mice treated with only CY, suggesting that AMH prevents PF activation through the mTOR pathway [ 58 ]. AMH shows minimal side effects because it is an endogenous hormone with activity limited to the ovaries.

5.1.4. Imatinib

Imatinib, a tyrosine kinase inhibitor used in cancer treatment, selectively inhibits the ABL kinase domain of the bcr-abl oncogenic protein present in patients with chronic myelogenous leukemia [ 131 ]. It is also known to inhibit cKIT and platelet-derived growth factor receptor tyrosine kinases in gastrointestinal stromal tumors [ 132 , 133 ]. As PF depletion by apoptosis or activation mechanisms are mainly mediated by the ABL/TAp63 and KIT/PI3K pathways, respectively, it can be hypothesized that imatinib might be able to prevent ovarian dysfunction caused by these pathways [ 134 ]. Previous studies have demonstrated that c-Abl helps maintain genomic integrity by managing DNA breaks [ 135 , 136 ]. Many studies have investigated the protective effects of imatinib, but conflicting results have been reported [ 137 , 138 , 139 ]. In PFs of postnatal day 5 mice, cisplatin induced c-Abl nuclear accumulation, increased TAp63 levels, and eventually caused cell apoptosis. Treatment with the c-Abl kinase inhibitor, imatinib, rescued cisplatin-induced depletion of the follicle reserve. The average number of pups and pregnancy rates were also higher in mice transplanted with ovarian tissue treated with combined cisplatin and imatinib [ 130 ]. However, in a similar mouse model study, the number of PFs and the average number of pups were not significantly higher in the group treated with imatinib in addition to cisplatin [ 133 ]. This conflicting result is thought to be due to the different types of cisplatin used in each study, and thus the toxicity to PFs at the same dose was different.

5.1.5. Sphingosine-1-Phosphate

Sphingosine-1-phosphate (S1P), a naturally occurring sphingolipid, inhibits the ceramide-promoted apoptotic pathway [ 140 ]. It increases vascularity and angiogenesis, and reduces PF apoptosis [ 69 ]. In mice xenotransplanted with human ovarian cortical tissue, the co-administration of S1P with cyclophosphamide and doxorubicin was associated with a lower rate of apoptosis. The authors analyzed the expression of activated caspase 3 using immunohistochemistry to evaluate the activation of apoptotic cell death pathways. The expression of activated caspase 3 in human ovarian tissue cotreated with S1P was significantly lower than that in the group treated with cyclophosphamide or doxorubicin alone [ 141 ]. It also showed a protective effect in mice treated with dacarbazine [ 142 ]. However, another study found no reduction in chemotherapy-induced follicle loss in S1P-treated rats [ 143 ].

5.1.6. Granulocyte Colony-Stimulating Factor

Granulocyte colony-stimulating factor (G-CSF) treatment significantly decreases the loss of PFs induced by chemotherapeutic agents, prevents damage to vascular structures, and reduces DNA damage in oocytes or growing follicles. In 6-week-old mice treated with high-dose alkylating chemotherapy (cyclophosphamide and busulfan), G-CSF with or without stem cell factor maintained PF numbers. G-CSF treatment with or without stem cell factor treatment decreases chemotherapy-induced gamma H2AX phosphorylation in early growing follicles, which is the earliest cellular response to DNA damage. G-CSF coadministration also increases microvessel density, as assessed by immunofluorescent staining for PECAM1/CD31 in vascular endothelial cells after chemotherapy treatment [ 69 , 144 ]. It also shows an anti-apoptotic effect; however, there is a concern that G-CSF may induce follicle loss associated with focal ischemia, fibrosis, and infarcts of blood vessels [ 69 , 145 ].

5.2. Prevention of Ovarian Damage before and during Radiation Treatment

5.2.1. Identifying the Location of the Ovaries

Technical improvements in radiotherapy have maximized target coverage while sparing normal organs using highly conformal dose distributions [ 73 ]. Identifying the location of the ovaries during treatment is essential for determining the dose administered to the ovaries during radiotherapy. In one study, ovaries were identified in 75% of the patients via an abdominal computed tomography (CT) scan [ 146 ]. However, the position of the ovary is affected by the contents of the bladder. Variations in the ovary position can result in their displacement to a high-dose irradiation field [ 147 ]. Therefore, daily on-board CT imaging may be used to map the ovary position before radiation treatment. Three-dimensional imaging provides relevant information for use in adaptive radiotherapy. Additionally, patient education regarding bladder filling before treatment would help not only to maintain an accurate radiation field for effective treatment but also to improve the protection of the ovaries [ 73 , 148 ].

5.2.2. Alternative Techniques for Craniospinal Radiotherapy

Craniospinal irradiation can induce gonadal damage [ 149 , 150 ]. Traditionally, craniospinal irradiation has been conducted using the standard posterior–anterior inferior spinal field. However, opposed lateral fields for the inferior spine help to reduce the radiation dose around the ovaries [ 151 ]. In other studies, proton therapy for craniospinal irradiation generated with a posterior–anterior proton beam stopping just after the thecal sac showed a reduced ovarian dose without an unexpected exit dose [ 152 , 153 , 154 ].

5.2.3. Ovarian Transposition

In certain situations, the ovaries may be located proximally to the lesion targeted by the high-dose radiation. The transposition of ovaries out of the fields, which is a procedure called oophoropexy, may help to protect the ovaries against radiation-induced damage [ 155 , 156 , 157 ], and it has been recommended for all AYAs requiring radiation [ 158 , 159 ]. Ovarian transposition has been recommended for patients with advanced cervical cancer who require radiotherapy, but only a quarter of patients younger than 40 years have undergone oophoropexy before treatment [ 160 , 161 , 162 , 163 ]. Laparoscopic techniques can be used to minimize surgical morbidity [ 164 , 165 ]. Ovaries are usually fixed to the anterolateral abdominal wall. During the procedure, the ovarian vessels should be carefully mobilized to avoid damage. Metallic clips are usually applied at the base of the transposed ovary [ 159 , 162 ]. As there is a risk of gonadal failure after pelvic irradiation following ovarian transposition, concurrent ovarian tissue cryopreservation during surgery is strongly recommended [ 166 ]. External beam radiation could be the main risk factor for ovarian failure even after transposition, and combined chemotherapy may aggravate the risk [ 74 , 162 , 167 ]. Ovarian transposition should be offered to all women who have a high possibility of radiation exposure near the ovaries. However, it should not be offered to women with poor ovarian reserve, with a high risk of ovarian metastasis, or who are scheduled for chemotherapy only.

5.3. Cryopreservation

5.3.1. Embryo Cryopreservation

Although ovarian damage can be reduced using the above-mentioned surgical or imaging-guided methods or via the administration of protective agents before chemotherapy, embryo cryopreservation is the most well-established method for preserving fertility [ 168 ]. Embryo freezing should initially be considered for FP treatment if there is adequate time for ovarian stimulation, and a partner or donor sperm is available [ 169 ]. This technique is safe and effective for patients undergoing assisted reproductive procedures [ 170 , 171 ]. Slow freezing and vitrification methods offer excellent results and are widely used [ 172 ]. Several studies have suggested that embryo vitrification and thawing methods are better than slow freezing and thawing methods in terms of pregnancy and live birth rates [ 173 , 174 , 175 ]. Many institutions prefer vitrification as a simpler and less expensive alternative to slow freezing, which requires the use of controlled-rate freezers and large quantities of liquid nitrogen.

Embryo cryopreservation requires ovarian stimulation; therefore, this option is not adequate for prepubertal girls. Additionally, embryo cryopreservation may not be appropriate for women who do not have a partner or do not want to use donor sperm. Furthermore, this technique may entail the risk of losing reproductive autonomy and present possible issues with the ownership of stored embryos. In patients with hormone-dependent breast cancer, aromatase inhibitors can be used as alternatives to ovarian stimulation [ 176 ]. If there is insufficient time for FP procedures before cancer treatment, random-start ovarian stimulation would be appropriate [ 177 , 178 , 179 ]. In studies comparing the results of in vitro fertilization and embryo cryopreservation in patients with cancer and those without cancer, contradictory results were observed in terms of fertilization and live birth rates [ 178 , 180 , 181 , 182 ].

5.3.2. Oocyte Cryopreservation

Oocyte cryopreservation is another widely used method, which is considered a standard technique for FP in patients with cancer [ 183 ]. The introduction of vitrification into assisted reproductive techniques has resulted in oocyte cryopreservation outcomes similar to those obtained with fresh oocytes [ 184 , 185 ]. In 2013, the American Society for Reproductive Medicine (ASRM) approved oocyte cryopreservation for FP based on the results of four clinical trials [ 186 , 187 , 188 , 189 ]. This technique has similar disadvantages to those of embryo cryopreservation because it involves ovarian stimulation, which makes it unsuitable for prepubertal girls. However, it can be utilized for women who are single or do not want sperm donation. Vitrification was more effective than slow freezing in avoiding crystallization because the former reduced cellular damage and chilling injury during the freezing process [ 189 , 190 ]. Accordingly, the National Institute for Health and Care Excellence guidelines recommend vitrification instead of controlled-rate freezing for oocyte cryopreservation, given the availability of the necessary equipment and expertise [ 191 ].

As oocyte freezing involves the removal of cumulus cells before cryopreservation, it can induce changes in the zona pellucida, which may affect the fertilization rates of conventional insemination. Therefore, ASRM recommends intracytoplasmic sperm injection for frozen oocytes as the preferred procedure [ 168 , 192 ].

The combination of oocyte cryopreservation and ovarian tissue cryopreservation can enhance the results of the FP procedure [ 193 ]. However, the cryopreservation of ovarian tissue concomitant with oocyte retrieval is ineffective; thus, it is not recommended after ovarian stimulation with human menopausal gonadotropin or recombinant FSH followed by human chorionic gonadotropin [ 194 , 195 ].

5.3.3. Ovarian Tissue Cryopreservation and Transplantation

Ovarian tissue cryopreservation is generally the only option for FP in children or AYAs with cancer who need immediate treatment and do not have enough time for ovarian stimulation and other procedures. Using this technique, a large number of oocytes, including PFs, can be preserved, and hormonal function of the ovary can be protected to improve the quality of life of the young patients [ 196 ].

Ovarian tissues are excised via biopsy, partial oophorectomy, or total oophorectomy, and are frozen for preservation before the initiation of cancer treatment [ 197 ]. To date, slow freezing has been established as the preferred method for ovarian tissue cryopreservation over vitrification [ 198 ]. However, several recent studies have shown promising results after vitrification [ 199 , 200 , 201 ]. A review of 60 cases showed that ovarian activity was restored in 92.9% of the cases after the transplantation of the ovarian tissue that was cryopreserved using the slow-freezing method [ 195 ]. After ovarian tissue transplantation, recovery of ovarian function has been reported, along with successful live births [ 183 ].

Oocyte cryopreservation is not suitable for patients with ovarian or hematologic malignancies because of the possible contamination of the ovarian tissue with malignant cells, as shown in several studies [ 202 , 203 ]. Nonetheless, ovarian tissue cryopreservation may be considered after an initial dose of chemotherapy to reduce the risk of malignant cell contamination, despite possible partial ovarian damage [ 204 ].

Recently, a study evaluated the changes in telomere length and senescence markers during ovarian tissue cryopreservation. The mean telomere length was significantly decreased after cryopreservation, and Western blot analysis indicated that senescence markers were affected by cryopreservation [ 205 ]. The possibility of irreversible DNA changes, such as the shortening of telomere length and alterations in senescence markers, should be considered when using this technique.

6. Future Perspectives on FP

6.1. Whole Ovarian Transplantation

Whole ovarian transplantation has the benefit of immediate revascularization following blood vessel anastomosis, thereby reducing ischemic injury; however, potential injury due to hypothermic damage to blood vessels and difficulties in dispersing a sufficient amount of cryoprotective agent make it challenging in clinical practice [ 206 , 207 ]. Successful whole ovarian cryopreservation and transplantation have been reported in animal studies, and whether vitrification or slow freezing is preferable for cryopreservation is still under debate [ 208 , 209 , 210 , 211 ]. Before whole ovarian transplantation can be established in clinical use, there may be several challenges to its adoption, including proficient and diligent use of surgical techniques and identifying optimal protocols for cryopreservation and thawing. To date, there has been no experimental model to explore techniques for the cryopreservation and retransplantation of human ovaries. Table 2 shows several studies that evaluated the feasibility of the xenotransplantation of human ovaries into animals for study purposes.

6.2. In Vitro Maturation

In vitro maturation (IVM) is usually used in patients with polycystic ovarian syndrome (PCOS). This requires immature oocyte retrieval and cryopreservation either at an immature stage or at a post-IVM mature state [ 242 ]. This can also be used in patients with cancer who lack adequate time for ovarian stimulation or prepubertal girls who need immediate treatment. Although many researchers have attempted to improve outcomes by combining IVM and vitrification, only a few live births have been reported after IVM procedures in patients with cancer [ 243 , 244 , 245 ]. Further technical improvements may allow the use of this technology for FP in the near future.

6.3. Artificial Ovaries

The transplantation of ovarian tissue with a scaffold accelerates tissue vascularization via the release of multiple bioactive materials [ 246 , 247 ]. Recently, this technique has been most commonly used to enable the transplantation of various substances or accessory cells, including stem cells, together with ovarian tissues [ 248 , 249 , 250 ]. Artificial ovaries can be useful for developing mature oocytes via multiple processes, including in vitro culture of oocytes, isolated follicles, and ovarian tissue [ 251 , 252 ]. In animal studies, this approach restored endocrine function, enabling in vivo follicle development and successful pregnancy; however, there have been no successful reports in humans [ 252 , 253 ]. Improvements in techniques and addressing genetic safety concerns are warranted for more consistent results in human applications.

6.4. Ovarian Stem Cells

Stem cells are being investigated for use in FP. One study reported the successful detection and isolation of ovarian stem cells in animals and humans [ 254 , 255 ]. Additionally, egg-producing stem cells isolated from ovaries differentiate into young oocytes [ 254 ]. This technique may provide another option for prepubertal children with cancer and women for whom conventional FP methods are not suitable. However, it is not commonly applied in clinical practice because of insufficient evidence in human-assisted reproduction, the scarcity of ovarian stem cells, and the ethical issues related to the use of oocytes and embryos [ 256 ]. Further studies are required to implement these approaches in clinical practice.

7. Conclusions

Improving our knowledge regarding the molecular mechanisms involved in cancer therapy-induced ovarian damage can lead to the development of treatments to limit follicular damage. Some of the molecular mechanisms involved in the protective effects of various agents are unclear. Although several studies have assessed the effect of disease and treatment on human ovaries, few studies have been conducted because of ethical concerns [ 257 , 258 ]. However, understanding the molecular etiology of treatment-induced ovarian dysfunction can not only aid in identifying targets to prevent and reduce gonadal damage during cancer treatment, but also increase the number of options for FP.

Gonadotoxic cancer treatments induce iatrogenic premature ovarian insufficiency and loss of fertility in prepubertal girls and AYAs with cancer. An individualized strategy including established and experimental techniques should be provided based on patient age, marital status, economic status, chemotherapy regimen, cancer type, staging upon diagnosis, and available time for the FP process to prevent loss of ovarian function and fertility.

Novel therapies are of great interest, as they may limit follicular loss and protect the ovaries before or during cancer treatment. These therapies could be utilized in combination with standard FP techniques, or they may be used alone in the future. These strategies can assist young women who are not eligible for traditional FP methods because of their age or limited time before the initiation of disease treatment. Effective multidisciplinary oncofertility strategies involving a highly skilled and experienced team composed of medical oncologists, gynecologists, reproductive biologists, surgeons, patient care coordinators, psychologists, and research scientists should be carefully considered for each patient to provide high-quality care.

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author Contributions

Writing—original draft preparation, S.K. and S.-W.K.; writing—review and editing, S.-W.K. and S.L.; conceptualization and visualization, S.L.; supervision, intellectual content, and paper coordination, S.-J.H., H.-T.P., J.-Y.S. and T.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the National Research Foundation of Korea Grant by the Korean Government (grant number NRF-2016R1C1B3015250).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Sung H. Ferlay J. Siegel R.L. Laversanne M. Soerjomataram I. Jemal A. Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin. 2021 71 209 249 10.3322/caac.21660 33538338

2. Miller K.D. Benaoudia M.F. Keegan T.H. Hipp H.S. Jemal A. Siegel R.L. Cancer statistics for adolescents and young adults CA Cancer J. Clin. 2020 70 443 459 10.3322/caac.21637 32940362

3. Birch J.M. Marsden H.B. Jones P.H. Pearson D. Blair V. Improvements in survival from childhood cancer: Results of a population based survey over 30 years Br. Med. J. (Clin. Res. Ed.) 1988 296 1372 1376 10.1136/bmj.296.6633.1372 PMC2545835 2840171

4. Wingo P.A. Ries L.A. Parker S.L. Heath C.W. Jr. Long-term cancer patient survival in the United States Cancer Epidemiol. Biomark. Prev. 1998 7 271 282 9568781

5. Sklar C.A. Mertens A.C. Mitby P. Whitton J. Stovall M. Kasper C. Mulder J. Green D. Nicholson H.S. Yasui Y. Premature menopause in survivors of childhood cancer: A report from the childhood cancer survivor study J. Natl. Cancer Inst. 2006 98 890 896 10.1093/jnci/djj243 16818852

6. Wallace W.H.B. Thomson A.B. Saran F. Kelsey T.W. Predicting age of ovarian failure after radiation to a field that includes the ovaries Int. J. Radiat. Oncol. Biol. Phys. 2005 62 738 744 10.1016/j.ijrobp.2004.11.038 15936554

7. Vriens I.J.H. de Bie A.J.R. Aarts M.J.B. de Boer M. van Hellemond I.E.G. Roijen J.H.E. van Golde R.J.T. Voogd A.C. Heijnen V.C.G.T. The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients Oncotarget 2017 8 11372 11379 10.18632/oncotarget.14532 28076330 PMC5355271

8. Chemaitilly W. Li Z. Krasin M.J. Brooke R.J. Wilson C.L. Green D.M. Klosky J.L. Barnes N. Clark K.L. Farr J.B. Premature Ovarian Insufficiency in Childhood Cancer Survivors: A Report From the St. Jude Lifetime Cohort J. Clin. Endocrinol. Metab. 2017 102 2242 2250 10.1210/jc.2016-3723 28368472 PMC5505200

9. Ganz P.A. Greendale G.A. Petersen L. Kahn B. Bower J.E. Breast cancer in younger women: Reproductive and late health effects of treatment J. Clin. Oncol. 2003 21 4184 4193 10.1200/JCO.2003.04.196 14615446

10. Muka T. Williams C.O. Kunutsor S. Laven J.S.E. Fauser B.C.J.M. Chowdhury R. Kavousi M. Franco O.H. Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis JAMA Cardiol. 2016 1 767 776 10.1001/jamacardio.2016.2415 27627190

11. Wu X. Cai H. Kallianpur A. Li H. Yang G. Gao J. Xiang Y.B. Ji B.T. Tang Y. Zheng W. Impact of premature ovarian failure on mortality and morbidity among Chinese women PLoS ONE 2014 9 e89597 10.1371/journal.pone.0089597 24603759 PMC3945971

12. Lee S. Heytens E. Moy F. Ozkavukcu S. Oktay K. Determinants of access to fertility preservation in women with breast cancer Fertil. Steril. 2011 95 1932 1936 10.1016/j.fertnstert.2011.01.169 21371704 PMC3383791

13. Lee S. Ozkavukcu S. Heytens E. Moy F. Oktay K. Value of early referral to fertility preservation in young women with breast cancer J. Clin. Oncol. 2010 28 4683 4686 10.1200/JCO.2010.30.5748 20876425 PMC3039918

14. Kim J. Oktay K. Gracia C. Lee S. Morse C. Mersereau J.E. Which patients pursue fertility preservation treatments? A multicenter analysis of the predictors of fertility preservation in women with breast cancer Fertil. Steril. 2012 97 671 676 10.1016/j.fertnstert.2011.12.008 22222194 PMC4191895

15. Oktay K. Harvey B.E. Partridge A.H. Quinn G.P. Reinecke J. Taylor H.S. Wallace W.H. Wang E.T. Loren A.W. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update J. Clin. Oncol. 2018 36 1994 2001 10.1200/JCO.2018.78.1914 29620997

16. Lee S. Kim S.K. Hwang K.J. Kim T. Kim S.H. Fertility preservation for patients with gynecologic malignancies: The Korean Society for Fertility Preservation clinical guidelines Clin. Exp. Reprod. Med. 2017 44 175 180 10.5653/cerm.2017.44.4.175 29376013 PMC5783913

17. Campbell S.B. Woodard T.L. An update on fertility preservation strategies for women with cancer Gynecol. Oncol. 2020 156 3 5 10.1016/j.ygyno.2019.11.001 31787247

18. Lambertini M. Peccatori F.A. Demeestere I. Amant F. Wyns C. Stukenborg J.-B. Paluch-Shimon S. Halaska M.J. Uzan C. Meissner J. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines(dagger) Ann. Oncol. 2020 31 1664 1678 10.1016/j.annonc.2020.09.006 32976936

19. Coccia P.F. Pappo A.S. Beaupin L. Borges V.F. Borinstein S.C. Chugh R. Dinner S. Folbrecht J. Frazier A.L. Goldsby R. Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology J. Natl. Compr. Canc. Netw. 2018 16 66 97 29295883 10.6004/jnccn.2018.0001

20. Letourneau J.M. Ebbel E.E. Katz P.P. Oktay K.H. McCulloch C.E. Ai W.Z. Chien A.J. Melisko M.E. Cedars M.I. Rosen M.P. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer Cancer 2012 118 1933 1939 10.1002/cncr.26403 21850728 PMC3220922

21. Davies C. Pan H. Godwin J. Gray R. Arriagada R. Raina V. Abraham M. Alencar V.H.M. Badran A. Bonfill X. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 2013 381 805 816 10.1016/S0140-6736(12)61963-1 23219286 PMC3596060

22. Stupart D. Win A.K. Jenkins M. Winship I.M. Female fertility and colorectal cancer Int. J. Colorectal. Dis. 2008 23 735 743 18458919 10.1007/s00384-008-0483-3

23. Zapardiel I. Cruz M. Diestro M.D. Requena A. Velasco J.A.G. Assisted reproductive techniques after fertility-sparing treatments in gynaecological cancers Hum. Reprod. Update 2016 22 281 305 10.1093/humupd/dmv066 26759231

24. Roness H. Kashi O. Meirow D. Prevention of chemotherapy-induced ovarian damage Fertil. Steril. 2016 105 20 29 10.1016/j.fertnstert.2015.11.043 26677788

25. Sonigo C. Beau I. Binart N. Grynberg M. The Impact of Chemotherapy on the Ovaries: Molecular Aspects and the Prevention of Ovarian Damage Int. J. Mol. Sci. 2019 20 5342 10.3390/ijms20215342 PMC6862107 31717833

26. Szymanska K.J. Tan X. Oktay K. Unraveling the mechanisms of chemotherapy-induced damage to human primordial follicle reserve: Road to developing therapeutics for fertility preservation and reversing ovarian aging Mol. Hum. Reprod. 2020 26 553 566 10.1093/molehr/gaaa043 32514568 PMC7411370

27. Cosgrove C.M. Salani R. Ovarian effects of radiation and cytotoxic chemotherapy damage Best Pract. Res. Clin. Obstet. Gynaecol. 2019 55 37 48 10.1016/j.bpobgyn.2018.07.008 30166215

28. Marci R. Mallozzi M. di Benedetto L. Schimberni M. Mossa S. Soave I. Palomba S. Caserta D. Radiations and female fertility Reprod. Biol. Endocrinol. 2018 16 112 10.1186/s12958-018-0432-0 30553277 PMC6295315

29. Bedoschi G. Navarro P.A. Oktay K. Chemotherapy-induced damage to ovary: Mechanisms and clinical impact Future Oncol. 2016 12 2333 2344 10.2217/fon-2016-0176 27402553 PMC5066134

30. Wallace W.H. Kelsey T.W. Human ovarian reserve from conception to the menopause PLoS ONE 2010 5 e8772 10.1371/journal.pone.0008772 20111701 PMC2811725

31. Reddy P. Zheng W. Liu K. Mechanisms maintaining the dormancy and survival of mammalian primordial follicles Trends Endocrinol. Metab. 2010 21 96 103 10.1016/j.tem.2009.10.001 19913438

32. Adhikari D. Liu K. Molecular mechanisms underlying the activation of mammalian primordial follicles Endocr. Rev. 2009 30 438 464 10.1210/er.2008-0048 19589950

33. McLaughlin M. Kinnell H.L. Anderson R.A. Telfer E.E. Inhibition of phosphatase and tensin homologue (PTEN) in human ovary in vitro results in increased activation of primordial follicles but compromises development of growing follicles Mol. Hum. Reprod. 2014 20 736 744 10.1093/molehr/gau037 24830779 PMC4106636

34. Li J. Kawamura K. Cheng Y. Liu S. Klein C. Liu S. Duan E. Hsueh A.J.W. Activation of dormant ovarian follicles to generate mature eggs Proc. Natl. Acad. Sci. USA 2010 107 10280 10284 10.1073/pnas.1001198107 20479243 PMC2890455

35. Hsueh A.J.W. Kawamura K. Cheng Y. Fauser B.C.J.M. Intraovarian control of early folliculogenesis Endocr. Rev. 2015 36 1 24 10.1210/er.2014-1020 25202833 PMC4309737

36. Gawriluk T.R. Hale A.N. Flaws J.A. Dillon C.P. Green D.R. Rucker E.B. 3rd Autophagy is a cell survival program for female germ cells in the murine ovary Reproduction 2011 141 759 765 21464117 10.1530/REP-10-0489

37. Kuma A. Hatano M. Matsui M. Yamamoto A. Nakaya H. Yoshimori T. Ohsumi Y. Tokuhisa T. Mizushima N. The role of autophagy during the early neonatal starvation period Nature 2004 432 1032 1036 10.1038/nature03029 15525940

38. De Vos M. Devroey P. Fauser B.C. Primary ovarian insufficiency Lancet 2010 376 911 921 10.1016/S0140-6736(10)60355-8 20708256

39. Chapman R.M. Effect of cytotoxic therapy on sexuality and gonadal function Semin. Oncol. 1982 9 84 94 6176028

40. Miller J.J. 3rd Williams G.F. Leissring J.C. Multiple late complications of therapy with cyclophosphamide, including ovarian destruction Am. J. Med. 1971 50 530 535 10.1016/0002-9343(71)90341-X 5313910

41. Rose D.P. Davis T.E. Ovarian function in patients receiving adjuvant chemotherapy for breast cancer Lancet 1977 1 1174 1176 10.1016/S0140-6736(77)92716-7 68275

42. Shalet S.M. Effects of cancer chemotherapy on gonadal function of patients Cancer Treat. Rev. 1980 7 141 152 10.1016/S0305-7372(80)80028-4 7004638

43. Koyama H. Wada T. Nishizawa Y. Iwanaga T. Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer Cancer 1977 39 1403 1409 10.1002/1097-0142(197704)39:4<1403::AID-CNCR2820390408>3.0.CO;2-8 851940

44. Andrieu J.M. Ochoa-Molina M.E. Menstrual cycle, pregnancies and offspring before and after MOPP therapy for Hodgkin’s disease Cancer 1983 52 435 438 10.1002/1097-0142(19830801)52:3<435::AID-CNCR2820520308>3.0.CO;2-1 6688036

45. Cho H.W. Lee S. Min K.J. Hong J.H. Song J.Y. Lee J.K. Lee N.W. Kim T. Advances in the Treatment and Prevention of Chemotherapy-Induced Ovarian Toxicity Int. J. Mol. Sci. 2020 21 7792 10.3390/ijms21207792 PMC7589665 33096794

46. Thomson A.B. Critchley H.O. Wallace W.H. Fertility and progeny Eur. J. Cancer 2002 38 1634–1644, discussion 1645–1646 10.1016/S0959-8049(02)00093-X 12142054

47. Morgan S. Anderson R.A. Gourley C. Wallace W.H. Spears N. How do chemotherapeutic agents damage the ovary? Hum. Reprod. Update 2012 18 525 535 10.1093/humupd/dms022 22647504

48. Winship A.L. Stringer J.M. Liew S.H. Hutt K.J. The importance of DNA repair for maintaining oocyte quality in response to anti-cancer treatments, environmental toxins and maternal ageing Hum. Reprod. Update 2018 24 119 134 10.1093/humupd/dmy002 29377997

49. Utsunomiya T. Tanaka T. Utsunomiya H. Umesaki N. A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis Int. J. Oncol. 2008 32 991 1000 10.3892/ijo.32.5.991 18425325

50. Kerr J.B. Hutt K.J. Michalak E.M. Cook M. Vandenberg C.J. Liew S.H. Bouillet P. Mills A. Scott C.L. Findlay J.K. DNA damage-induced primordial follicle oocyte apoptosis and loss of fertility require TAp63-mediated induction of Puma and Noxa Mol. Cell 2012 48 343 352 10.1016/j.molcel.2012.08.017 23000175 PMC3496022

51. Oktem O. Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve Cancer Res. 2007 67 10159 10162 10.1158/0008-5472.CAN-07-2042 17974956

52. Petrillo S.K. Desmeules P. Truong T.Q. Devine P.J. Detection of DNA damage in oocytes of small ovarian follicles following phosphoramide mustard exposures of cultured rodent ovaries in vitro Toxicol. Appl. Pharmacol. 2011 253 94 102 10.1016/j.taap.2011.03.012 21439308

53. Ganesan S. Keating A.F. The ovarian DNA damage repair response is induced prior to phosphoramide mustard-induced follicle depletion, and ataxia telangiectasia mutated inhibition prevents PM-induced follicle depletion Toxicol. Appl. Pharmacol. 2016 292 65 74 10.1016/j.taap.2015.12.010 26708502

54. Nguyen Q.N. Zerafa N. Liew S.H. Findlay J.K. Hickey M. Hutt K.J. Cisplatin- and cyclophosphamide-induced primordial follicle depletion is caused by direct damage to oocytes Mol. Hum. Reprod. 2019 25 433 444 10.1093/molehr/gaz020 30953068

55. Soleimani R. Heytens E. Darzynkiewicz Z. Oktay K. Mechanisms of chemotherapy-induced human ovarian aging: Double strand DNA breaks and microvascular compromise Aging 2011 3 782 793 10.18632/aging.100363 21869459 PMC3184979

56. Roness H. Gavish Z. Cohen Y. Meirow D. Ovarian follicle burnout: A universal phenomenon? Cell Cycle 2013 12 3245 3246 10.4161/cc.26358 24036538 PMC3885633

57. Chen X.Y. Xia H.X. Guan H.Y. Li B. Zhang W. Follicle Loss and Apoptosis in Cyclophosphamide-Treated Mice: What’s the Matter? Int. J. Mol. Sci. 2016 17 836 10.3390/ijms17060836 PMC4926370 27248997

58. Sonigo C. Beau I. Grynberg M. Binart N. AMH prevents primordial ovarian follicle loss and fertility alteration in cyclophosphamide-treated mice FASEB J. 2019 33 1278 1287 10.1096/fj.201801089R 30113879

59. Sobinoff A.P. Nixon B. Roman S.D. McLaughlin E.A. Staying alive: PI3K pathway promotes primordial follicle activation and survival in response to 3MC-induced ovotoxicity Toxicol. Sci. 2012 128 258 271 10.1093/toxsci/kfs137 22505044

60. Chang E.M. Lim E. Yoon S. Jeong K. Bae S. Lee D.R. Yoon T.K. Choi Y. Lee W.S. Cisplatin Induces Overactivation of the Dormant Primordial Follicle through PTEN/AKT/FOXO3a Pathway which Leads to Loss of Ovarian Reserve in Mice PLoS ONE 2015 10 e0144245 10.1371/journal.pone.0144245 26656301 PMC4699462

61. Jang H. Na Y. Hong K. Lee S. Moon S. Cho M. Park M. Lee O.H. Chang E.M. Lee D.R. Synergistic effect of melatonin and ghrelin in preventing cisplatin-induced ovarian damage via regulation of FOXO3a phosphorylation and binding to the p27(Kip1) promoter in primordial follicles J. Pineal. Res. 2017 63 10.1111/jpi.12432 28658519

62. Kitajima M. Dolmans M.M. Donnez O. Masuzaki H. Soares M. Donnez J. Enhanced follicular recruitment and atresia in cortex derived from ovaries with endometriomas Fertil. Steril. 2014 101 1031 1037 10.1016/j.fertnstert.2013.12.049 24502890

63. Marcello M.F. Nuciforo G. Romeo R. di Dino G. Russo I. Russo A. Palumbo G. Schilirò G. Structural and ultrastructural study of the ovary in childhood leukemia after successful treatment Cancer 1990 66 2099 2104 10.1002/1097-0142(19901115)66:10<2099::AID-CNCR2820661010>3.0.CO;2-3 2224764

64. Doll D.C. Ringenberg Q.S. Yarbro J.W. Vascular toxicity associated with antineoplastic agents J. Clin. Oncol. 1986 4 1405 1417 10.1200/JCO.1986.4.9.1405 3528405

65. Nicosia S.V. Matus-Ridley M. Meadows A.T. Gonadal effects of cancer therapy in girls Cancer 1985 55 2364 2372 10.1002/1097-0142(19850515)55:10<2364::AID-CNCR2820551011>3.0.CO;2-E 3986739

66. Aharon I.B. Meizner I. Granot T. Uri S. Hasky N. Rizel S. Yerushalmi R. Sulkes A. Stemmer S.M. Chemotherapy-induced ovarian failure as a prototype for acute vascular toxicity Oncologist 2012 17 1386 1393 10.1634/theoncologist.2012-0172 22956534 PMC3500358

67. Meirow D. Dor J. Kaufman B. Shrim A. Rabinovici J. Schiff E. Raanani H. Levron J. Fridman E. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury Hum. Reprod. 2007 22 1626 1633 10.1093/humrep/dem027 17324957

68. Oktay K. Oktem O. Reh A. Vahdat L. Measuring the impact of chemotherapy on fertility in women with breast cancer J. Clin. Oncol. 2006 24 4044 4046 10.1200/JCO.2006.06.9823 16921067

69. Soleimani R. Heytens E. Oktay K. Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants PLoS ONE 2011 6 e19475 10.1371/journal.pone.0019475 21559342 PMC3084884

70. Howell S. Shalet S. Gonadal damage from chemotherapy and radiotherapy Endocrinol. Metab. Clin. N. Am. 1998 27 927 943 10.1016/S0889-8529(05)70048-7 9922915

71. Madsen B.L. Giudice L. Donaldson S.S. Radiation-induced premature menopause: A misconception Int. J. Radiat. Oncol. Biol. Phys. 1995 32 1461 1464 10.1016/0360-3016(95)00025-T 7635789

72. Beerendonk C.C.M. Braat D.D.M. Present and future options for the preservation of fertility in female adolescents with cancer Endocr. Dev. 2005 8 166 175 15722624 10.1159/000084101

73. Stroud J.S. Mutch D. Rader J. Powell M. Thaker P.H. Grigsby P.W. Effects of cancer treatment on ovarian function Fertil. Steril. 2009 92 417 427 10.1016/j.fertnstert.2008.07.1714 18774559

74. Wallace W.H. Thomson A.B. Kelsey T.W. The radiosensitivity of the human oocyte Hum. Reprod. 2003 18 117 121 10.1093/humrep/deg016 12525451

75. Lushbaugh C.C. Casarett G.W. The effects of gonadal irradiation in clinical radiation therapy: A review Cancer 1976 37 Suppl. 2 1111 1125 10.1002/1097-0142(197602)37:2+<1111::AID-CNCR2820370821>3.0.CO;2-E 766956

76. Wo J.Y. Viswanathan A.N. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients Int. J. Radiat. Oncol. Biol. Phys. 2009 73 1304 1312 10.1016/j.ijrobp.2008.12.016 19306747 PMC2865903

77. Hall E.J. Cancer caused by x-rays—A random event? Lancet Oncol. 2007 8 369 370 10.1016/S1470-2045(07)70113-4 17466892

78. Maier P. Hartmann L. Wenz F. Herskind C. Cellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor Radiosensitization Int. J. Mol. Sci. 2016 17 102 10.3390/ijms17010102 PMC4730344 26784176

79. Alhumaidha K.A. Saleh D.O. el Fattah M.A.A. el Eraky W.I. Moawad H. Cardiorenal protective effect of taurine against cyclophosphamide-induced toxicity in albino rats Can. J. Physiol. Pharmacol. 2016 94 131 139 10.1139/cjpp-2015-0138 26695545

80. Kumar M. Pathak D. Venkatesh S. Kriplani A. Ammini A.C. Dada R. Chromosomal abnormalities & oxidative stress in women with premature ovarian failure (POF) Indian J. Med. Res. 2012 135 92 97 22382189 10.4103/0971-5916.93430 PMC3307192

81. Devine P.J. Perreault S.D. Luderer U. Roles of reactive oxygen species and antioxidants in ovarian toxicity Biol. Reprod. 2012 86 27 10.1095/biolreprod.111.095224 22034525 PMC3290661

82. Pala Ş. Atilgan R. Kuloğlu T. Kara M. Başpinar M. Can B. Artaş G. Protective effects of vitamin C and vitamin E against hysterosalpingography-induced epithelial degeneration and proliferation in rat endometrium Drug Des. Devel. Ther. 2016 10 4079 4089 10.2147/DDDT.S117207 PMC5170617 28008231

83. Nambiar D. Rajamani P. Singh R.P. Effects of phytochemicals on ionization radiation-mediated carcinogenesis and cancer therapy Mutat. Res. 2011 728 139 157 10.1016/j.mrrev.2011.07.005 22030216

84. Kim B.M. Hong Y. Lee S. Liu P. Lim J.H. Lee Y.H. Lee T.H. Chang K.T. Hong Y. Therapeutic Implications for Overcoming Radiation Resistance in Cancer Therapy Int. J. Mol. Sci. 2015 16 26880 26913 10.3390/ijms161125991 26569225 PMC4661850

85. Mantawy E.M. Said R.S. Abdel-Aziz A.K. Mechanistic approach of the inhibitory effect of chrysin on inflammatory and apoptotic events implicated in radiation-induced premature ovarian failure: Emphasis on TGF-beta/MAPKs signaling pathway Biomed. Pharmacother. 2019 109 293 303 10.1016/j.biopha.2018.10.092 30396087

86. Jaroudi S. Kakourou G. Cawood S. Doshi A. Ranieri D.M. Serhal P. Harper J.C. SenGupta S.B. Expression profiling of DNA repair genes in human oocytes and blastocysts using microarrays Hum. Reprod. 2009 24 2649 2655 10.1093/humrep/dep224 19542543

87. Duncan F.E. Kimler B.F. Briley S.M. Combating radiation therapy-induced damage to the ovarian environment Future Oncol. 2016 12 1687 1690 10.2217/fon-2016-0121 27117319 PMC5549657

88. Petrek J.A. Naughton M.J. Case L.D. Paskett E.D. Naftalis E.Z. Singletary S.E. Sukumvanich P. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study J. Clin. Oncol. 2006 24 1045 1051 10.1200/JCO.2005.03.3969 16476708

89. Anderson R.A. Wallace W.H. Antimullerian hormone, the assessment of the ovarian reserve, and the reproductive outcome of the young patient with cancer Fertil. Steril. 2013 99 1469 1475 10.1016/j.fertnstert.2013.03.014 23541317

90. Gracia C.R. Sammel M.D. Freeman E. Prewitt M. Carlson C. Ray A. Vance A. Ginsberg J.P. Impact of cancer therapies on ovarian reserve Fertil. Steril. 2012 97 134 140.e1 10.1016/j.fertnstert.2011.10.040 22137491 PMC4005036

91. Kevenaar M.E. Meerasahib M.F. Kramer P. Born B.M.N.V. de Jong F.H. Groome N.P. Themmen A.P.N. Visser J.A. Serum anti-mullerian hormone levels reflect the size of the primordial follicle pool in mice Endocrinology 2006 147 3228 3234 10.1210/en.2005-1588 16556768

92. Peñarrubia J. Fábregues F. Manau D. Creus M. Casals G. Casamitjana R. Carmona F. Vanrell J.A. Balasch J. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist—Gonadotropin treatment Hum. Reprod. 2005 20 915 922 10.1093/humrep/deh718 15665015

93. Peigne M. Decanter C. Serum AMH level as a marker of acute and long-term effects of chemotherapy on the ovarian follicular content: A systematic review Reprod. Biol. Endocrinol. 2014 12 26 10.1186/1477-7827-12-26 24666685 PMC3987687

94. D’Avila Â.M. Biolchi V. Capp E. Corleta H.V. Age, anti-mullerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide J. Ovarian. Res. 2015 8 82 10.1186/s13048-015-0209-4 26667243 PMC4678664

95. Anders C. Marcom P.K. Peterson B. Gu L. Unruhe S. Welch R. Lyons P. Behera M. Copland S. Kimmick G. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer Cancer Investig. 2008 26 286 295 10.1080/07357900701829777 18317970 PMC2883164

96. Anderson R.A. Cameron D.A. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer J. Clin. Endocrinol. Metab. 2011 96 1336 1343 10.1210/jc.2010-2582 21325458

97. Toner J.P. Seifer D.B. Why we may abandon basal follicle-stimulating hormone testing: A sea change in determining ovarian reserve using antimullerian hormone Fertil. Steril. 2013 99 1825 1830 10.1016/j.fertnstert.2013.03.001 23548941

98. Nelson S.M. Biomarkers of ovarian response: Current and future applications Fertil. Steril. 2013 99 963 969 10.1016/j.fertnstert.2012.11.051 23312225

99. Jung M. Shin H.J. Rha S.Y. Jeung H.C. Hong S. Moon Y.W. Kim H.S. Oh K.J. Yang W.I. Roh J.K. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up Ann. Surg. Oncol. 2010 17 3259 3268 10.1245/s10434-010-1172-3 20563656

100. Broekmans F.J. Kwee J. Hendriks D.J. Mol B.W. Lambalk C.B. A systematic review of tests predicting ovarian reserve and IVF outcome Hum. Reprod. Update 2006 12 685 718 10.1093/humupd/dml034 16891297

101. Knauff E.A.H. Eijkemans M.J.C. Lambalk C.B. Booij M.J.t.K. Hoek A. Beerendonk C.C.M. Laven J.S.E. Goverde A.J. Broekmans F.J.M. Themmen A.P.N. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure J. Clin. Endocrinol. Metab. 2009 94 786 792 10.1210/jc.2008-1818 19066296

102. Muttukrishna S. McGarrigle H. Wakim R. Khadum I. Ranieri D.M. Serhal P. Antral follicle count, anti-mullerian hormone and inhibin B: Predictors of ovarian response in assisted reproductive technology? BJOG 2005 112 1384 1390 10.1111/j.1471-0528.2005.00670.x 16167941

103. Frattarelli J.L. Levi A.J. Miller B.T. Segars J.H. A prospective assessment of the predictive value of basal antral follicles in in vitro fertilization cycles Fertil. Steril. 2003 80 350 355 10.1016/S0015-0282(03)00664-2 12909498

104. Magon N. Gonadotropin releasing hormone agonists: Expanding vistas Indian J. Endocrinol. Metab. 2011 15 261 267 10.4103/2230-8210.85575 22028996 PMC3193774

105. Blumenfeld Z. Dann E. GnRH agonist for the prevention of chemotherap.y-induced ovarian failure in lymphoma J. Clin. Oncol. 2013 31 3721 10.1200/JCO.2012.47.8222 24002509

106. Blumenfeld Z. Avivi I. Linn S. Epelbaum R. Shahar M.B. Haim N. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy Hum. Reprod. 1996 11 1620 1626 10.1093/oxfordjournals.humrep.a019457 8921104

107. Pacheco B.P. Ribas J.M.M. Milone G. Fernández I. Kvicala R. Mila T. di Noto A. Ortiz O.C. Pavlovsky S. Use of GnRH analogs for functional protection of the ovary and preservation of fertility during cancer treatment in adolescents: A preliminary report Gynecol. Oncol. 2001 81 391 397 10.1006/gyno.2001.6181 11371127

108. Recchia F. Sica G. de Filippis S. Saggio G. Rosselli M. Rea S. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: A phase II pilot study Anticancer Drugs 2002 13 417 424 10.1097/00001813-200204000-00011 11984088

109. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries Oncologist 2007 12 1044 1054 10.1634/theoncologist.12-9-1044 17914074

110. Blumenfeld Z. Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a J. Natl. Cancer Inst. Monogr. 2005 2005 40 43 10.1093/jncimonographs/lgi015 15784821

111. Lambertini M. Horicks F. del Mastro L. Partridge A.H. Demeestere I. Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application Cancer Treat. Rev. 2019 72 65 77 10.1016/j.ctrv.2018.11.006 30530271

112. Blumenfeld Z. Fertility preservation and GnRHa for chemotherapy: Debate Cancer Manag. Res. 2014 6 313 315 10.2147/CMAR.S66600 25170279 PMC4144983

113. Oktay K. Sönmezer M. Oktem O. Fox K. Emons G. Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury Oncologist 2007 12 1055 1066 10.1634/theoncologist.12-9-1055 17914075

114. Bedaiwy M.A. Abou-Setta A.M. Desai N. Hurd W. Starks D. El-Nashar S.A. al Inany H.G. Falcone T. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: A systematic review and meta-analysis Fertil. Steril. 2011 95 906 914 10.1016/j.fertnstert.2010.11.017 21145541

115. Chen H. Xiao L. Li J. Cui L. Huang W. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women Cochrane Database Syst. Rev. 2019 3 CD008018 10.1002/14651858.CD008018.pub3 30827035 PMC6397718

116. Clowse M.E.B. Behera M.A. Anders C.K. Copland S. Coffman C.J. Leppert P.C. Bastian L.A. Ovarian preservation by GnRH agonists during chemotherapy: A meta-analysis J. Womens Health 2009 18 311 319 10.1089/jwh.2008.0857 PMC2858300 19281314

117. Del Mastro L. Boni L. Michelotti A. Gamucci T. Olmeo N. Gori S. Giordano M. Garrone O. Pronzato P. Bighin C. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: A randomized trial JAMA 2011 306 269 276 10.1001/jama.2011.991 21771987

118. De Pedro M. Otero B. Martin B. Fertility preservation and breast cancer: A review Ecancermedicalscience 2015 9 503 10.3332/ecancer.2015.503 25729416 PMC4335963

119. Peccatori F.A. Azim H.A. Jr. Orecchia R. Hoekstra H.J. Pavlidis N. Kesic V. Pentheroudakis G. ESMO Guidelines Working Group Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann. Oncol. 2013 24 Suppl. 6 vi160 vi170 10.1093/annonc/mdt199 23813932

120. Woodruff T.K. The Oncofertility Consortium—Addressing fertility in young people with cancer Nat. Rev. Clin. Oncol. 2010 7 466 475 10.1038/nrclinonc.2010.81 20498666 PMC3124936

121. Makarovsky D. Kalechman Y. Sonino T. Freidkin I. Teitz S. Albeck M. Weil M. Geffen-Aricha R. Yadid G. Sredni B. Tellurium compound AS101 induces PC12 differentiation and rescues the neurons from apoptotic death Ann. N. Y. Acad. Sci. 2003 1010 659 666 10.1196/annals.1299.120 15033807

122. Hayun M. Naor Y. Weil M. Albeck M. Peled A. Don J. Haran-Ghera N. Sredni B. The immunomodulator AS101 induces growth arrest and apoptosis in multiple myeloma: Association with the Akt/survivin pathway Biochem. Pharmacol. 2006 72 1423 1431 10.1016/j.bcp.2006.06.015 16889755

123. Philosoph L.K. Roness H. Carmely A. Fishel-Bartal M. Ligumsky H. Paglin S. Wolf I. Kanety H. Sredni B. Meirow D. Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility Sci. Transl. Med. 2013 5 185ra62 10.1126/scitranslmed.3005402 23677591

124. Kalechman Y. Shani A. Barkai I.S. Albeck M. Sredni B. The protective role of ammonium trichloro(dioxoethylene-O,O’)tellurate in combination with several cytotoxic drugs acting by different mechanisms of action Cancer Res. 1993 53 5962 5969 8261410

125. Kalechman Y. Barkai I.S. Albeck M. Sredni B. Protection of bone marrow stromal cells from the toxic effects of cyclophosphamide in vivo and of ASTA-Z 7557 and etoposide in vitro by ammonium trichloro(dioxyethylene-O-O’)tellurate (AS101) Cancer Res. 1993 53 1838 1844 8467503

126. Sredni B. Albeck M. Kazimirsky G. Shalit F. The immunomodulator AS101 administered orally as a chemoprotective and radioprotective agent Int. J. Immunopharmacol. 1992 14 613 619 10.1016/0192-0561(92)90122-2 1521929

127. Kalechman Y. Albeck M. Oron M. Sobelman D. Gurwith M. Horwith G. Kirsch T. Maida B. Sehgal S.N. Sredni B. Protective and restorative role of AS101 in combination with chemotherapy Cancer Res. 1991 51 1499 1503 1997189

128. Carlsson I.B. Scott J.E. Visser J.A. Ritvos O. Themmen A.P.N. Hovatta O. Anti-Mullerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro Hum. Reprod. 2006 21 2223 2237 10.1093/humrep/del165 16720622

129. Durlinger A.L.L. Gruijters M.J.G. Kramer P. Karels B. Ingraham H.A. Nachtigal M.W. Uilenbroek J.J. Grootegoed J.A. Themmen A.P.N. Anti-Mullerian hormone inhibits initiation of primordial follicle growth in the mouse ovary Endocrinology 2002 143 1076 1084 10.1210/endo.143.3.8691 11861535

130. Durlinger A.L. Kramer P. Karels B. de Jong F.H. Uilenbroek J.T. Grootegoed J.A. Themmen A.P. Control of primordial follicle recruitment by anti-Mullerian hormone in the mouse ovary Endocrinology 1999 140 5789 5796 10.1210/endo.140.12.7204 10579345

131. Druker B.J. Tamura S. Buchdunger E. Ohno S. Segal G.M. Fanning S. Zimmermann J. Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells Nat. Med. 1996 2 561 566 10.1038/nm0596-561 8616716

132. Demetri G.D. von Mehren M. Blanke C.D. van den Abbeele A.D. Eisenberg B. Roberts P.J. Heinrich M.C. Tuveson D.A. Singer S. Janicek M. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N. Engl. J. Med. 2002 347 472 480 10.1056/NEJMoa020461 12181401

133. Jaeckle K.A. Anderson S.K. Twohy E.L. Dixon J.G. Giannini C. Jenkins R. Egorin M.J. Sarkaria J.N. Brown P.D. Flynn P.J. Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG) J. Neurooncol. 2019 143 573 581 10.1007/s11060-019-03194-z 31119479 PMC6717651

134. Gonfloni S. di Tella L. Caldarola S. Cannata S.M. Klinger F.G. di Bartolomeo C. Mattei M. Candi E. de Felici M. Melino G. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death Nat. Med. 2009 15 1179 1185 10.1038/nm.2033 19783996

135. Kharbanda S. Pandey P. Morris P.L. Whang Y. Xu Y. Sawant S. Zhu L.J. Kumar N. Yuan Z.M. Weichselbaum R. Functional role for the c-Abl tyrosine kinase in meiosis I Oncogene 1998 16 1773 1777 10.1038/sj.onc.1201934 9583675

136. Kharbanda S. Yuan Z.M. Weichselbaum R. Kufe D. Determination of cell fate by c-Abl activation in the response to DNA damage Oncogene 1998 17 3309 3318 10.1038/sj.onc.1202571 9916993

137. Kerr J.B. Hutt K.J. Cook M. Speed T.P. Strasser A. Findlay J.K. Scott C.L. Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib Nat. Med. 2012 18 1170 1172 10.1038/nm.2889 22869179 PMC3517916

138. Kim S.-Y. Cordeiro M.H. Serna V.A. Ebbert K. Butler L.M. Sinha S. Mills A.A. Woodruff T.K. Kurita T. Rescue of platinum-damaged oocytes from programmed cell death through inactivation of the p53 family signaling network Cell Death Differ. 2013 20 987 997 10.1038/cdd.2013.31 23598363 PMC3705595

139. Morgan S. Lopes F. Gourley C. Anderson R.A. Spears N. Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin PLoS ONE 2013 8 e70117 10.1371/journal.pone.0070117 23922929 PMC3726485

140. Morita Y. Perez G.I. Paris F. Miranda S.R. Ehleiter D. Haimovitz-Friedman A. Fuks Z. Xie Z. Reed J.C. Schuchman E.H. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy Nat. Med. 2000 6 1109 1114 10.1038/80442 11017141

141. Li F. Turan V. Lierman S. Cuvelier C. de Sutter P. Affiliations K.O. Sphingosine-1-phosphate prevents chemotherapy-induced human primordial follicle death Hum. Reprod. 2014 29 107 113 10.1093/humrep/det391 24221908 PMC3860896

142. Hancke K. Strauch O. Kissel C. Göbel H. Schäfer W. Denschlag D. Sphingosine 1-phosphate protects ovaries from chemotherapy-induced damage in vivo Fertil. Steril. 2007 87 172 177 10.1016/j.fertnstert.2006.06.020 17081530

143. Kaya H. Desdicioglu R. Sezik M. Ulukaya E. Ozkaya O. Yilmaztepe A. Demirci M. Does sphingosine-1-phosphate have a protective effect on cyclophosphamide- and irradiation-induced ovarian damage in the rat model? Fertil. Steril. 2008 89 732 735 10.1016/j.fertnstert.2007.03.065 17517398

144. Wikiel M.E.S. McGuire M.M. Sukhwani M. Donohue J. Chu T. Krivak T.C. Rajkovic A. Orwig K.E. Granulocyte colony-stimulating factor with or without stem cell factor extends time to premature ovarian insufficiency in female mice treated with alkylating chemotherapy Fertil. Steril. 2013 99 2045 2054.e3 10.1016/j.fertnstert.2013.01.135 23453120 PMC3672312

145. Solaroglu I. Cahill J. Jadhav V. Zhang J.H. A novel neuroprotectant granulocyte-colony stimulating factor Stroke 2006 37 1123 1128 10.1161/01.STR.0000208205.26253.96 16514095

146. Rigsby C.K. Siegel M.J. CT appearance of pediatric ovaries and uterus J. Comput. Assist. Tomogr. 1994 18 72 76 10.1097/00004728-199401000-00016 8282889

147. Nicholson R. Coucher J. Thornton A. Connor F. Effect of a full and empty bladder on radiation dose to the uterus, ovaries and bladder from lumbar spine CT and X-ray examinations Br. J. Radiol. 2000 73 1290 1296 10.1259/bjr.73.876.11205673 11205673

148. Kim S. Lee S. Hong J.H. Park Y.J. Song J.Y. Lee J.K. Lee N.W. Comparing efficacy of high-dose rate brachytherapy versus helical tomotherapy in the treatment of cervical cancer J. Gynecol. Oncol. 2020 31 e42 10.3802/jgo.2020.31.e42 32026658 PMC7286762

149. Hamre M.R. Robison L.L. Nesbit M.E. Sather H.N. Meadows A.T. Ortega J.A. D’Angio G.J. Hammond G.D. Effects of radiation on ovarian function in long-term survivors of childhood acute lymphoblastic leukemia: A report from the Childrens Cancer Study Group J. Clin. Oncol. 1987 5 759 765 10.1200/JCO.1987.5.11.1759 3119785

150. Livesey E.A. Brook C.G. Gonadal dysfunction after treatment of intracranial tumours Arch. Dis. Child. 1988 63 495 500 10.1136/adc.63.5.495 3389863 PMC1778926

151. Harden S.V. Twyman N. Lomas D.J. Williams D. Burnet N.G. Williams M.V. A method for reducing ovarian doses in whole neuro-axis irradiation for medulloblastoma Radiother. Oncol. 2003 69 183 188 10.1016/j.radonc.2003.10.002 14643956

152. Lee C.T. Bilton S.D. Famiglietti R.M. Riley B.A. Mahajan A. Chang E.L. Maor M.H. Woo S.Y. Cox J.D. Smith A.R. Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: How do protons compare with other conformal techniques? Int. J. Radiat. Oncol. Biol. Phys. 2005 63 362 372 10.1016/j.ijrobp.2005.01.060 16168831

153. Miralbell R. Lomax A. Bortfeld T. Rouzaud M. Carrie C. Potential role of proton therapy in the treatment of pediatric medulloblastoma/primitive neuroectodermal tumors: Reduction of the supratentorial target volume Int. J. Radiat. Oncol. Biol. Phys. 1997 38 477 484 10.1016/S0360-3016(97)00004-7 9231669

154. Yuh G.E. Loredo L.N. Yonemoto L.T. Bush D.A. Shahnazi K. Preston W. Slater J.M. Slater J.D. Reducing toxicity from craniospinal irradiation: Using proton beams to treat medulloblastoma in young children Cancer J. 2004 10 386 390 10.1097/00130404-200411000-00009 15701271

155. Hadar H. Loven D. Herskovitz P. Bairey O. Yagoda A. Levavi H. An evaluation of lateral and medial transposition of the ovaries out of radiation fields Cancer 1994 74 774 779 10.1002/1097-0142(19940715)74:2<774::AID-CNCR2820740234>3.0.CO;2-H 8033059

156. Le Floch O. Donaldson S.S. Kaplan H.S. Pregnancy following oophoropexy and total nodal irradiation in women with Hodgkin’s disease Cancer 1976 38 2263 2268 10.1002/1097-0142(197612)38:6<2263::AID-CNCR2820380612>3.0.CO;2-S 826312

157. Thibaud E. Ramirez M. Brauner R. Flamant F. Zucker J.M. Fékété C. Rappaport R. Preservation of ovarian function by ovarian transposition performed before pelvic irradiation during childhood J. Pediatr. 1992 121 880 884 10.1016/S0022-3476(05)80332-4 1447649

158. Loren A.W. Mangu P.B. Beck L.N. Brennan L. Magdalinski A.J. Partridge A.H. Quinn G. Wallace W.H. Oktay K. American Society of Clinical Oncology Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update J. Clin. Oncol. 2013 31 2500 2510 10.1200/JCO.2013.49.2678 23715580 PMC5321083

159. Morice P. Ba R.T. Castaigne D. Haie-Meder C. Gerbaulet A. Pautier P. Duvillard P. Michel G. Fertility results after ovarian transposition for pelvic malignancies treated by external irradiation or brachytherapy Hum. Reprod. 1998 13 660 663 10.1093/humrep/13.3.660 9572430

160. Al-Asari S. Abduljabbar A. Laparoscopic ovarian transposition before pelvic radiation in rectal cancer patient: Safety and feasibility Ann. Surg. Innov. Res. 2012 6 9 10.1186/1750-1164-6-9 22985942 PMC3499289

161. Dursun P. Ayhan A. Yanik F.B. Kuşçu E. Ovarian transposition for the preservation of ovarian function in young patients with cervical carcinoma Eur. J. Gynaecol. Oncol. 2009 30 13 15 19317249

162. Morice P. Juncker L. Rey A. El-Hassan J. Haie-Meder C. Castaigne D. Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination Fertil. Steril. 2000 74 743 748 10.1016/S0015-0282(00)01500-4 11020517

163. Han S.S. Kim Y.H. Lee S.H. Kim G.J. Kim H.J. Kim J.W. Park N.H. Song Y.S. Kang S.B. Underuse of ovarian transposition in reproductive-aged cancer patients treated by primary or adjuvant pelvic irradiation J. Obstet. Gynaecol. Res. 2011 37 825 829 10.1111/j.1447-0756.2010.01443.x 21450024

164. Scott S.M. Schlaff W. Laparoscopic medial oophoropexy prior to radiation therapy in an adolescent with Hodgkin’s disease J. Pediatr. Adolesc. Gynecol. 2005 18 355 357 10.1016/j.jpag.2005.06.009 16202940

165. Williams R.S. Littell R.D. Mendenhall N.P. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease Cancer 1999 86 2138 2142 10.1002/(SICI)1097-0142(19991115)86:10<2138::AID-CNCR36>3.0.CO;2-V 10570443

166. Bisharah M. Tulandi T. Laparoscopic preservation of ovarian function: An underused procedure Am. J. Obstet. Gynecol. 2003 188 367 370 10.1067/mob.2003.38 12592241

167. Wallace W.H. Anderson R.A. Irvine D.S. Fertility preservation for young patients with cancer: Who is at risk and what can be offered? Lancet Oncol. 2005 6 209 218 10.1016/S1470-2045(05)70092-9 15811616

168. Gook D.A. Edgar D.H. Human oocyte cryopreservation Hum. Reprod. Update 2007 13 591 605 10.1093/humupd/dmm028 17846105

169. de Vos M. Smitz J. Woodruff T.K. Fertility preservation in women with cancer Clin. Exp. Reprod. Med. 2012 39 46 51 10.1016/S0140-6736(14)60834-5 22816069 PMC3398116

170. Cakmak H. Rosen M.P. Ovarian stimulation in cancer patients Fertil. Steril. 2013 99 1476 1484 10.1016/j.fertnstert.2013.03.029 23635348

171. Devroey P. Polyzos N.P. Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment Hum. Reprod. 2011 26 2593 2597 10.1093/humrep/der251 21828116

172. Roque M. Lattes K. Serra S. Solà I. Geber S. Carreras R. Checa M.A. Fresh embryo transfer versus frozen embryo transfer in in vitro fertilization cycles: A systematic review and meta-analysis Fertil. Steril. 2013 99 156 162 10.1016/j.fertnstert.2012.09.003 23040524

173. Rienzi L. Gracia C. Maggiulli R. LaBarbera A.R. Kaser D.J. Ubaldi F.M. Vanderpoel S. Racowsky C. Oocyte, embryo and blastocyst cryopreservation in ART: Systematic review and meta-analysis comparing slow-freezing versus vitrification to produce evidence for the development of global guidance Hum. Reprod. Update 2017 23 139 155 10.1093/humupd/dmw038 27827818 PMC5850862

174. AbdelHafez F.F. Desai N. Setta A.M.A. Falcone T. Goldfarb J. Slow freezing, vitrification and ultra-rapid freezing of human embryos: A systematic review and meta-analysis Reprod. Biomed. Online 2010 20 209 222 10.1016/j.rbmo.2009.11.013 20113959

175. Debrock S. Peeraer K. Gallardo E.F. de Neubourg D. Spiessens C. D’Hooghe T.M. Vitrification of cleavage stage day 3 embryos results in higher live birth rates than conventional slow freezing: A RCT Hum. Reprod. 2015 30 1820 1830 10.1093/humrep/dev134 26089301

176. Lee S. Oktay K. Does higher starting dose of FSH stimulation with letrozole improve fertility preservation outcomes in women with breast cancer? Fertil. Steril. 2012 98 961 964.e1 10.1016/j.fertnstert.2012.06.015 22771027 PMC3777251

177. Chung K. Donnez J. Ginsburg E. Meirow D. Emergency IVF versus ovarian tissue cryopreservation: Decision making in fertility preservation for female cancer patients Fertil. Steril. 2013 99 1534 1542 10.1016/j.fertnstert.2012.11.057 23517859

178. Courbiere B. Decanter C. Deutsch S.B. Rives N. Mirallié S. Pech J.C. de Ziegler D. Pigeon F.C. Panloup P.M. Sifer C. Emergency IVF for embryo freezing to preserve female fertility: A French multicentre cohort study Hum. Reprod. 2013 28 2381 2388 10.1093/humrep/det268 23832792

179. Cakmak H. Katz A. Cedars M.I. Rosen M.P. Effective method for emergency fertility preservation: Random-start controlled ovarian stimulation Fertil. Steril. 2013 100 1673 1680 10.1016/j.fertnstert.2013.07.1992 23987516

180. Oktay K. Cil A.P. Bang H. Efficiency of oocyte cryopreservation: A meta-analysis Fertil. Steril. 2006 86 70 80 10.1016/j.fertnstert.2006.03.017 16818031

181. Dolmans M.M. de Ouderaen S.H. Demylle D. Pirard C. Utilization rates and results of long-term embryo cryopreservation before gonadotoxic treatment J. Assist. Reprod. Genet. 2015 32 1233 1237 10.1007/s10815-015-0533-z 26174124 PMC4554374

182. Mayeur A. Puy V. Windal V. Hesters L. Gallot V. Benoit A. Grynberg M. Sonigo C. Frydman N. Live birth rate after use of cryopreserved oocytes or embryos at the time of cancer diagnosis in female survivors: A retrospective study of ten years of experience J. Assist. Reprod. Genet. 2021 10.1007/s10815-021-02168-3 33797007 PMC8324734

183. Kim S. Lee Y. Lee S. Kim T. Ovarian tissue cryopreservation and transplantation in patients with cancer Obstet. Gynecol. Sci. 2018 61 431 442 10.5468/ogs.2018.61.4.431 30018897 PMC6046360

184. Cobo A. Velasco J.A.G. Domingo J. Remohí J. Pellicer A. Is vitrification of oocytes useful for fertility preservation for age-related fertility decline and in cancer patients? Fertil. Steril. 2013 99 1485 1495 10.1016/j.fertnstert.2013.02.050 23541405

185. Cobo A. Diaz C. Clinical application of oocyte vitrification: A systematic review and meta-analysis of randomized controlled trials Fertil. Steril. 2011 96 277 285 10.1016/j.fertnstert.2011.06.030 21718983

186. Parmegiani L. Cognigni G.E. Bernardi S. Cuomo S. Ciampaglia W. Infante F.E. de Fatis C.T. Arnone A. Maccarini A.M. Filicori M. Efficiency of aseptic open vitrification and hermetical cryostorage of human oocytes Reprod. Biomed. Online 2011 23 505 512 10.1016/j.rbmo.2011.07.003 21843968

187. Cobo A. Kuwayama M. Pérez S. Ruiz A. Pellicer A. Remohí J. Comparison of concomitant outcome achieved with fresh and cryopreserved donor oocytes vitrified by the Cryotop method Fertil. Steril. 2008 89 1657 1664 10.1016/j.fertnstert.2007.05.050 17889865

188. Cobo A. Meseguer M. Remohí J. Pellicer A. Use of cryo-banked oocytes in an ovum donation programme: A prospective, randomized, controlled, clinical trial Hum. Reprod. 2010 25 2239 2246 10.1093/humrep/deq146 20591872

189. Rienzi L. Romano S. Albricci L. Maggiulli R. Capalbo A. Baroni E. Colamaria S. Sapienza F. Ubaldi F. Embryo development of fresh ‘versus’ vitrified metaphase II oocytes after ICSI: A prospective randomized sibling-oocyte study Hum. Reprod. 2010 25 66 73 10.1093/humrep/dep346 19861328 PMC2794665

190. Ubaldi F. Anniballo R. Romano S. Baroni E. Albricci L. Colamaria S. Capalbo A. Sapienza F. Vajta G. Rienzi L. Cumulative ongoing pregnancy rate achieved with oocyte vitrification and cleavage stage transfer without embryo selection in a standard infertility program Hum. Reprod. 2010 25 1199 1205 10.1093/humrep/deq046 20185513 PMC2854047

191. National Collaborating Centre for Women’s and Children’s Health National Collaborating Centre for Women’s and Children’s Health. National Institute for Health and Clinical Excellence: Guidance Fertility: Assessment and Treatment for People with Fertility Problems Royal College of Obstetricians & Gynaecologists London, UK 2013 25340218

192. Practice Committees of the American Society for Reproductive Medicine The Society for Assisted Reproductive Technology Intracytoplasmic sperm injection (ICSI) for non-male factor indications: A committee opinion Fertil. Steril. 2020 114 239 245 10.1016/j.fertnstert.2020.05.032 32654822

193. Dittrich R. Lotz L. Mueller A. Hoffmann I. Wachter D.L. Amann K.U. Beckmann M.W. Hildebrandt T. Oncofertility: Combination of ovarian stimulation with subsequent ovarian tissue extraction on the day of oocyte retrieval Reprod. Biol. Endocrinol. 2013 11 19 10.1186/1477-7827-11-19 23510640 PMC3599192

194. Sánchez M. Maestre E.N. Teruel J. Ortiz E. Pellicer A. The Valencia Programme for Fertility Preservation Clin. Transl. Oncol. 2008 10 433 438 10.1007/s12094-008-0227-4 18628073

195. Donnez J. Dolmans M.M. Pellicer A. Garcia C.D. Serrano M.S. Schmidt K.T. Ernst E. Luyckx V. Andersen C.Y. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue: A review of 60 cases of reimplantation Fertil. Steril. 2013 99 1503 1513 10.1016/j.fertnstert.2013.03.030 23635349

196. Suzuki N. Ovarian tissue cryopreservation in young cancer patients for fertility preservation Reprod. Med. Biol. 2015 14 1 4 10.1007/s12522-014-0187-z 29259397 PMC5715820

197. Corkum K.S. Laronda M.M. Rowell E.E. A review of reported surgical techniques in fertility preservation for prepubertal and adolescent females facing a fertility threatening diagnosis or treatment Am. J. Surg. 2017 214 695 700 10.1016/j.amjsurg.2017.06.013 28683892 PMC6003699

198. Lee S. Ryu K.J. Kim B. Kang D. Kim Y.Y. Kim T. Comparison between Slow Freezing and Vitrification for Human Ovarian Tissue Cryopreservation and Xenotransplantation Int. J. Mol. Sci. 2019 20 3346 10.3390/ijms20133346 PMC6651588 31288388

199. Isachenko V. Isachenko E. Weiss J.M. Human ovarian tissue: Vitrification versus conventional freezing Hum. Reprod. 2009 24 1767 1768 10.1093/humrep/dep094 19386631

200. Keros V. Xella S. Hultenby K. Pettersson K. Sheikhi M. Volpe A. Hreinsson J. Hovatta O. Vitrification versus controlled-rate freezing in cryopreservation of human ovarian tissue Hum. Reprod. 2009 24 1670 1683 10.1093/humrep/dep079 19359339

201. Klocke S. Bündgen N. Köster F. Eichenlaub-Ritter U. Griesinger G. Slow-freezing versus vitrification for human ovarian tissue cryopreservation Arch. Gynecol. Obstet. 2015 291 419 426 10.1007/s00404-014-3390-6 25115279

202. Dolmans M.M. Luyckx V. Donnez J. Andersen C.Y. Greve T. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue Fertil. Steril. 2013 99 1514 1522 10.1016/j.fertnstert.2013.03.027 23541406

203. Loren A.W. Senapati S. Fertility preservation in patients with hematologic malignancies and recipients of hematopoietic cell transplants Blood 2019 134 746 760 10.1182/blood.2018846790 31292116

204. Rosendahl M. Andersen M.T. Ralfkiær E. Kjeldsen L. Andersen M.K. Andersen C.Y. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia Fertil. Steril. 2010 94 2186 2190 10.1016/j.fertnstert.2009.11.032 20100619

205. Kim B. Ryu K.J. Lee S. Kim T. Changes in telomere length and senescence markers during human ovarian tissue cryopreservation Sci. Rep. 2021 11 2238 10.1038/s41598-021-81973-3 33500500 PMC7838193

206. Bedaiwy M.A. Falcone T. Ovarian tissue banking for cancer patients: Reduction of post-transplantation ischaemic injury: Intact ovary freezing and transplantation Hum. Reprod. 2004 19 1242 1244 10.1093/humrep/deh262 15117897

207. Madrid B.M. Dolmans M.M. van Langendonckt A. Defrère S. Donnez J. Freeze-thawing intact human ovary with its vascular pedicle with a passive cooling device Fertil. Steril. 2004 82 1390 1394 10.1016/j.fertnstert.2004.06.036 15533365

208. Yin H. Wang X. Kim S.S. Chen H. Tan S.L. Gosden R.G. Transplantation of intact rat gonads using vascular anastomosis: Effects of cryopreservation, ischaemia and genotype Hum. Reprod. 2003 18 1165 1172 10.1093/humrep/deg236 12773441

209. Zhang J.M. Sheng Y. Cao Y.Z. Wang H.Y. Chen Z.J. Cryopreservation of whole ovaries with vascular pedicles: Vitrification or conventional freezing? J. Assist. Reprod. Genet. 2011 28 445 452 10.1007/s10815-011-9539-3 21287401 PMC3151356

210. Zhang S. Yao H. Liu Y. Ren L. Xiang D. Wang Y. Hypothermic machine perfusion after static cold storage improves ovarian function in rat ovarian tissue transplantation J. Assist. Reprod. Genet. 2020 37 1745 1753 10.1007/s10815-020-01797-4 32430732 PMC7376786

211. Hossay C. Donnez J. Dolmans M.M. Whole Ovary Cryopreservation and Transplantation: A Systematic Review of Challenges and Research Developments in Animal Experiments and Humans J. Clin. Med. 2020 9 3196 10.3390/jcm9103196 PMC7601276 33023111

212. Soleimani R. Heytens E. van den Broecke R. Rottiers I. Dhont M. Cuvelier C.A. de Sutter P. Xenotransplantation of cryopreserved human ovarian tissue into murine back muscle Hum. Reprod. 2010 25 1458 1470 10.1093/humrep/deq055 20299384

213. Gook D.A. Edgar D.H. Borg J. Archer J. Lutjen P.J. McBain J.C. Oocyte maturation, follicle rupture and luteinization in human cryopreserved ovarian tissue following xenografting Hum. Reprod. 2003 18 1772 1781 10.1093/humrep/deg365 12923127

214. Gook D.A. Edgar D.H. Borg J. Archer J. McBain J.C. Diagnostic assessment of the developmental potential of human cryopreserved ovarian tissue from multiple patients using xenografting Hum. Reprod. 2005 20 72 78 10.1093/humrep/deh550 15471928

215. Lotz L. Schneider H. Hackl J. Wachter D. Hoffmann I. Jurgons R. Beckmann M.W. Dittrich R. Does stimulation with human gonadotropins and gonadotropin-releasing hormone agonist enhance and accelerate the developmental capacity of oocytes in human ovarian tissue xenografted into severe combined immunodeficient mice? Fertil. Steril. 2014 101 1477 1484 10.1016/j.fertnstert.2014.01.038 24602750

216. Kim S.S. Kang H.G. Kim N.H. Lee H.C. Lee H.H. Assessment of the integrity of human oocytes retrieved from cryopreserved ovarian tissue after xenotransplantation Hum. Reprod. 2005 20 2502 2508 15946997 10.1093/humrep/dei099

217. Ayuandari S. Crepaz K.W. Paulitsch M. Wagner C. Zavadil C. Manzl C. Ziehr S.C. Wildt L. Tollinger S.H. Follicular growth after xenotransplantation of cryopreserved/thawed human ovarian tissue in SCID mice: Dynamics and molecular aspects J. Assist. Reprod. Genet. 2016 33 1585 1593 10.1007/s10815-016-0769-2 27465301 PMC5171895

218. Terada Y. Sato Y.T. Yoshimoto T.K. Hasegawa H. Ugajin T. Koyanagi Y. Ito M. Murakami T. Sasano H. Yaegashi N. Development of human Graafian follicles following transplantation of human ovarian tissue into NOD/SCID/gammac null mice Am. J. Reprod. Immunol. 2008 60 534 540 10.1111/j.1600-0897.2008.00653.x 19032615

219. Dolmans M.M. Yuan W.Y. Camboni A. Torre A. van Langendonckt A. Madrid B.M. Donnez J. Development of antral follicles after xenografting of isolated small human preantral follicles Reprod. Biomed. Online 2008 16 705 711 10.1016/S1472-6483(10)60485-3 18492376

220. Oktay K. Newton H. Mullan J. Gosden R.G. Development of human primordial follicles to antral stages in SCID/hpg mice stimulated with follicle stimulating hormone Hum. Reprod. 1998 13 1133 1138 10.1093/humrep/13.5.1133 9647533

221. David A. Dolmans M.M. van Langendonckt A. Donnez J. Amorim C.A. Immunohistochemical localization of growth factors after cryopreservation and 3 weeks’ xenotransplantation of human ovarian tissue Fertil. Steril. 2011 95 1241 1246 10.1016/j.fertnstert.2010.06.007 20638058

222. Weissman A. Gotlieb L. Colgan T. Jurisicova A. Greenblatt E.M. Casper R.F. Preliminary experience with subcutaneous human ovarian cortex transplantation in the NOD-SCID mouse Biol. Reprod. 1999 60 1462 1467 10.1095/biolreprod60.6.1462 10330106

223. Dath C. van Eyck A.S. Dolmans M.M. Romeu L. Vigne L.D. Donnez J. van Langendonckt A. Xenotransplantation of human ovarian tissue to nude mice: Comparison between four grafting sites Hum. Reprod. 2010 25 1734 1743 10.1093/humrep/deq131 20511300

224. Paulini F. Vilela J.M.V. Chiti M.C. Donnez J. Jadoul P. Dolmans M.M. Amorim C.A. Survival and growth of human preantral follicles after cryopreservation of ovarian tissue, follicle isolation and short-term xenografting Reprod. Biomed. Online 2016 33 425 432 10.1016/j.rbmo.2016.05.003 27210771

225. Amorim C.A. David A. Dolmans M.M. Camboni A. Donnez J. van Langendonckt A. Impact of freezing and thawing of human ovarian tissue on follicular growth after long-term xenotransplantation J. Assist. Reprod. Genet. 2011 28 1157 1165 10.1007/s10815-011-9672-z 22105186 PMC3241841

226. Jafarabadi M. Abdollahi M. Salehnia M. Assessment of vitrification outcome by xenotransplantation of ovarian cortex pieces in gamma-irradiated mice: Morphological and molecular analyses of apoptosis J. Assist. Reprod. Genet. 2015 32 195 205 10.1007/s10815-014-0382-1 25392074 PMC4354182

227. Campos P.H.A. Jr. Alves T.J.M. Dias M.T. Assunçao C.M. Munk M. Mattos M.S. Kraemer L.R. Almeida B.G. Russo R.C. Barcelos L. Ovarian Grafts 10 Days after Xenotransplantation: Folliculogenesis and Recovery of Viable Oocytes PLoS ONE 2016 11 e0158109 27362486 10.1371/journal.pone.0158109 PMC4928796

228. van Eyck A.S. Bouzin C. Feron O. Romeu L. van Langendonckt A. Donnez J. Dolmans M.M. Both host and graft vessels contribute to revascularization of xenografted human ovarian tissue in a murine model Fertil. Steril. 2010 93 1676 1685 10.1016/j.fertnstert.2009.04.048 19539913

229. Hormozi M. Talebi S. Zarnani A.H. Tehrani M.J. Gohari L.H. Soltanghoraei H. Jafarabadi M. Akhondi M.M. 5’-(N-ethylcarboxamido) adenosine improves angiogenesis in transplanted human ovarian tissue Fertil. Steril. 2011 95 2560 2563.e1–5 10.1016/j.fertnstert.2011.05.041 21704211

230. Fonseca H.H. Bosch P. Sirisathien S. Wininger J.D. Massey J.B. Brackett B.G. Effect of site of transplantation on follicular development of human ovarian tissue transplanted into intact or castrated immunodeficient mice Fertil. Steril. 2004 81 Suppl. 1 888 892 10.1016/j.fertnstert.2003.10.017 15019825

231. Maltaris T. Koelbl H. Fischl F. Seufert R. Schmidt M. Kohl J. Beckmann M.W. Binder H. Hoffmann I. Mueller A. Xenotransplantation of human ovarian tissue pieces in gonadotropin-stimulated SCID mice: The effect of ovariectomy Anticancer Res. 2006 26 4171 4176 17201129

232. Friedman O. Orvieto R. Fisch B. Felz C. Freud E. Haroush A.B. Abir R. Possible improvements in human ovarian grafting by various host and graft treatments Hum. Reprod. 2012 27 474 482 10.1093/humrep/der385 22114111

233. Fu S. Wang J. Sun W. Xu Y. Zhou X. Cheng W. Preclinical humanized mouse model with ectopic ovarian tissues Exp. Ther. Med. 2014 8 742 746 10.3892/etm.2014.1819 25120592 PMC4113642

234. van Langendonckt A. Romeu L. Ambroise J. Amorim C. Bearzatto B. Gala J.L. Donnez J. Dolmans M.M. Gene expression in human ovarian tissue after xenografting Mol. Hum. Reprod. 2014 20 514 525 10.1093/molehr/gau015 24586055

235. Wang L. Ying Y.F. Ouyang Y.L. Wang J.F. Xu J. VEGF and bFGF increase survival of xenografted human ovarian tissue in an experimental rabbit model J. Assist. Reprod. Genet. 2013 30 1301 1311 10.1007/s10815-013-0043-9 24062194 PMC3824857

236. Ruan X. Cui Y. Du J. Jin J. Gu M. Chen S. Mueck A.O. Randomized study to prove the quality of human ovarian tissue cryopreservation by xenotransplantation into mice J. Ovarian Res. 2019 12 46 10.1186/s13048-019-0521-5 31113493 PMC6530171

237. Luyckx V. Durant J.F. Camboni A. Gilliaux S. Amorim C.A. van Langendonckt A. Irenge L.M. Gala J.L. Donnez J. Dolmans M.M. Is transplantation of cryopreserved ovarian tissue from patients with advanced-stage breast cancer safe? A pilot study J. Assist. Reprod. Genet. 2013 30 1289 1299 10.1007/s10815-013-0065-3 23989997 PMC3824859

238. Kim S.S. Radford J. Harris M. Varley J. Rutherford A.J. Lieberman B. Shalet S. Gosden R. Ovarian tissue harvested from lymphoma patients to preserve fertility may be safe for autotransplantation Hum. Reprod. 2001 16 2056 2060 10.1093/humrep/16.10.2056 11574491

239. Greve T. Wielenga V.T. Grauslund M. Sørensen N. Christiansen D.B. Rosendahl M. Andersen C.Y. Ovarian tissue cryopreserved for fertility preservation from patients with Ewing or other sarcomas appear to have no tumour cell contamination Eur. J. Cancer 2013 49 1932 1938 10.1016/j.ejca.2013.01.032 23452988

240. Lotz L. Montag M. van der Ven H. von Wolff M. Mueller A. Hoffmann I. Wachter D. Beckmann M.W. Dittrich R. Xenotransplantation of cryopreserved ovarian tissue from patients with ovarian tumors into SCID mice--no evidence of malignant cell contamination Fertil. Steril. 2011 95 2612 2614.e1 10.1016/j.fertnstert.2011.05.003 21621205

241. Dolmans M.M. Marinescu C. Saussoy P. van Langendonckt A. Amorim C. Donnez J. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe Blood 2010 116 2908 2914 10.1182/blood-2010-01-265751 20595517

242. Lee J.A. Barritt J. Moschini R.M. Slifkin R.E. Copperman A.B. Optimizing human oocyte cryopreservation for fertility preservation patients: Should we mature then freeze or freeze then mature? Fertil. Steril. 2013 99 1356 1362 10.1016/j.fertnstert.2012.11.042 23266213

243. Son W.Y. Henderson S. Cohen Y. Dahan M. Buckett W. Immature Oocyte for Fertility Preservation Front. Endocrinol. 2019 10 464 10.3389/fendo.2019.00464 PMC6650526 31379739

244. Prasath E.B. Chan M.L.H. Wong W.H.W. Lim C.J.W. Tharmalingam M.D. Hendricks M. Loh S.F. Chia Y.N. First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient Hum. Reprod. 2014 29 276 278 10.1093/humrep/det420 24327539

245. Uzelac P.S. Delaney A.A. Christensen G.L. Bohler H.C.L. Nakajima S.T. Live birth following in vitro maturation of oocytes retrieved from extracorporeal ovarian tissue aspiration and embryo cryopreservation for 5 years Fertil. Steril. 2015 104 1258 1260 10.1016/j.fertnstert.2015.07.1148 26297647

246. Tavana S. Azarnia M. Valojerdi M.R. Shahverdi A. Hyaluronic acid-based hydrogel scaffold without angiogenic growth factors enhances ovarian tissue function after autotransplantation in rats Biomed. Mater. 2016 11 055006 10.1088/1748-6041/11/5/055006 27710922

247. Tavana S. Valojerdi M.R. Azarnia M. Shahverdi A. Restoration of ovarian tissue function and estrous cycle in rat after autotransplantation using hyaluronic acid hydrogel scaffold containing VEGF and bFGF Growth Factors 2016 34 97 106 10.1080/08977194.2016.1194835 27362476

248. Manavella D.D. Cacciottola L. Pommé S. Desmet C.M. Jordan B.F. Donnez J. Amorim C.A. Dolmans M.M. Two-step transplantation with adipose tissue-derived stem cells increases follicle survival by enhancing vascularization in xenografted frozen-thawed human ovarian tissue Hum. Reprod. 2018 33 1107 1116 10.1093/humrep/dey080 29635371

249. Damous L.L. Nakamuta J.S. de Carvalho A.E.T.S. Carvalho K.C. José M.S. Jr. Simões M.D. Krieger J.E. Baracat E.C. Scaffold-based delivery of adipose tissue-derived stem cells in rat frozen-thawed ovarian autografts: Preliminary studies in a rat model J. Assist. Reprod. Genet. 2015 32 1285 1294 10.1007/s10815-015-0527-x 26206456 PMC4554376

250. Manavella D.D. Cacciottola L. Payen V.L. Amorim C.A. Donnez J. Dolmans M.M. Adipose tissue-derived stem cells boost vascularization in grafted ovarian tissue by growth factor secretion and differentiation into endothelial cell lineages Mol. Hum. Reprod. 2019 25 184 193 10.1093/molehr/gaz008 30824937

251. Cho E. Kim Y.Y. Noh K. Ku S.Y. A new possibility in fertility preservation: The artificial ovary J. Tissue Eng. Regen. Med. 2019 13 1294 1315 10.1002/term.2870 31062444

252. Luyckx V. Dolmans M.M. Vanacker J. Legat C. Moya C.F. Donnez J. Amorim C.A. A new step toward the artificial ovary: Survival and proliferation of isolated murine follicles after autologous transplantation in a fibrin scaffold Fertil. Steril. 2014 101 1149 1156 10.1016/j.fertnstert.2013.12.025 24462059

253. Vanacker J. Luyckx V. Dolmans M.M. Rieux A.D. Jaeger J. van Langendonckt A. Donnez J. Amorim C.A. Transplantation of an alginate-matrigel matrix containing isolated ovarian cells: First step in developing a biodegradable scaffold to transplant isolated preantral follicles and ovarian cells Biomaterials 2012 33 6079 6085 10.1016/j.biomaterials.2012.05.015 22658800

254. Johnson J. Canning J. Kaneko T. Pru J.K. Tilly J.L. Germline stem cells and follicular renewal in the postnatal mammalian ovary Nature 2004 428 145 150 10.1038/nature02316 15014492

255. Tilly J.L. Telfer E.E. Purification of germline stem cells from adult mammalian ovaries: A step closer towards control of the female biological clock? Mol. Hum. Reprod. 2009 15 393 398 10.1093/molehr/gap036 19509111 PMC2696346

256. Hutt K.J. Albertini D.F. Clinical applications and limitations of current ovarian stem cell research: A review J. Exp. Clin. Assist. Reprod. 2006 3 6 10.1186/1743-1050-3-6 16872542 PMC1553467

257. Himelstein-Braw R. Peters H. Faber M. Morphological study of the ovaries of leukaemic children Br. J. Cancer 1978 38 82 87 10.1038/bjc.1978.166 687521 PMC2009696

258. Familiari G. Caggiati A. Nottola S.A. Ermini M. di Benedetto M.R. Motta P.M. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin’s disease Hum. Reprod. 1993 8 2080 2087 10.1093/oxfordjournals.humrep.a137985 8150906